



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/53, 9/02, 5/10, 1/19	A1	(11) International Publication Number: WO 00/23596 (43) International Publication Date: 27 April 2000 (27.04.00)
(21) International Application Number: PCT/US99/24873 (22) International Filing Date: 22 October 1999 (22.10.99) (30) Priority Data: 09/177,419 22 October 1998 (22.10.98) US (71) Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM [US/US]; 201 West 7th Street, Austin, TX 78701 (US). (72) Inventors: RUSSELL, David, W.; U.T. Southwestern Medical Center, Dept. Molecular Genetics, 5323 Harry Hines Boulevard, Dallas, TX 75235-9046 (US). LUND, Erik, G.; U.T. Southwestern Medical Center, Dept. Molecular Genetics, 5323 Harry Hines Boulevard, Dallas, TX 75235-9046 (US). (74) Agent: OSMAN, Richard, Aron; Science & Technology Law Group, 75 Denise Drive, Hillsborough, CA 94010 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: CHOLESTEROL 25-HYDROXYLASE (57) Abstract <p>The invention provides methods and compositions relating to cholesterol 25-hydroxylase polypeptides having cholesterol 25-hydroxylase-specific structure and activity, related polynucleotides and modulators of cholesterol 25-hydroxylase function and serum cholesterol. The invention provides isolated cholesterol 25-hydroxylase hybridization probes and primers capable of specifically hybridizing with natural cholesterol 25-hydroxylase genes, cholesterol 25-hydroxylase-specific binding agents such as specific antibodies, agonists and antagonists, and methods of making and using the subject compositions in diagnosis (e.g. genetic hybridization screens for cholesterol 25-hydroxylase transcripts), therapy (e.g. cholesterol 25-hydroxylase inhibitors to modulate serum cholesterol) and in the biopharmaceutical industry (e.g. as immunogens, reagents for isolating natural 25-hydroxylase genes and transcripts, reagents for screening chemical libraries for lead pharmacological agents, etc.).</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Cholesterol 25-Hydroxylase

The research described in this application was supported in part by NIH grant HL20948. The US government may have rights in any patent issuing on this application.

INTRODUCTION

Field of the Invention

The field of this invention is cholesterol regulation.

Background

Oxysterols are formed by the hydroxylation of the side chain of cholesterol. This modification renders the sterol more hydrophilic and confers two important biological properties. First, the increased hydrophilicity enhances the ability of the oxysterol to cross membranes and thereby facilitates its movement between intracellular compartments, cells and tissues. Second, oxysterols delivered in ethanol to cultured cells, are potent regulators of the expression of genes involved in sterol and fatty acid metabolism (1,2).

The enhanced solubility of oxysterols is exploited by the body to maintain cholesterol homeostasis. In several tissues and cell types, including the brain, kidney, endothelium, and macrophages, cholesterol is converted into oxysterols that subsequently traverse the plasma membrane and are transported to the liver (3-5). In the liver, they are converted into bile acids by a newly described biosynthetic pathway (6). These bile acids are essential for normal lipid and fat-soluble vitamin metabolism (7).

Oxysterols are both positive and negative regulators of gene expression. As positive effectors, they bind to and activate the nuclear receptor LXR (8), which in turn increases transcription of the cholesterol 7 α -hydroxylase gene (9). This activation stimulates the conversion of cholesterol into bile acids (10). Mutation of the LXR gene in mice causes a loss of 7 α -hydroxylase gene induction and a buildup of cholesterol in the liver (11). As negative regulators, oxysterols suppress the cleavage of two transcription factors known as sterol regulatory element binding proteins -1 and -2 (SREBP -1 and -2) (12). These proteins are synthesized as inactive precursors in the membrane compartment of the cell. When intracellular cholesterol levels decline, SREBPs are cleaved to release amino-terminal fragments that migrate to the nucleus and activate the transcription of a network of genes

involved in cholesterol synthesis and supply (12). This activation in turn restores intracellular cholesterol levels.

Several oxysterols occur naturally, including 25-hydroxycholesterol (cholest-5-ene-3 β ,25-diol), 24-hydroxycholesterol (cholest-5-ene-3 β ,24-diol), and 27-hydroxycholesterol (cholest-5-ene-3 β ,27-diol) (13). Of these three oxysterols, 25-hydroxycholesterol is the most potent regulator of gene transcription when assayed in vitro (1,2,9,11). Hence, 25-hydroxycholesterol biosynthetic enzymes would provide attractive targets for therapeutic inhibitor development, i.e. novel hypocholesteremic agents: by blocking 25-hydroxycholesterol synthesis, SREBPs remain in their active forms and stimulate expression of the LDL receptor, which in turn extracts LDL from the plasma, lowering serum cholesterol.

SUMMARY OF THE INVENTION

The invention provides methods and compositions relating to cholesterol 25-hydroxylase polypeptides having cholesterol 25-hydroxylase-specific structure and activity, related polynucleotides and modulators of cholesterol 25-hydroxylase function and serum cholesterol. For example, the subject cholesterol 25-hydroxylase polypeptides and polynucleotides can be used to regulate cholesterol 25-hydroxylase activity, and hence serum cholesterol in a mammalian host. The polypeptides may be recombinantly produced from transformed host cells from the subject cholesterol 25-hydroxylase polypeptide encoding nucleic acids or purified from natural sources such as mammalian cells. The invention provides isolated cholesterol 25-hydroxylase hybridization probes and primers capable of specifically hybridizing with natural cholesterol 25-hydroxylase genes, cholesterol 25-hydroxylase-specific binding agents such as specific antibodies, agonists and antagonists, cholesterol 25-hydroxylase transcriptional regulators, and methods of making and using the subject compositions in diagnosis (e.g. genetic hybridization screens for cholesterol 25-hydroxylase transcripts), therapy (e.g. cholesterol 25-hydroxylase inhibitors to modulate serum cholesterol) and in the biopharmaceutical industry (e.g. as immunogens, reagents for isolating natural 25-hydroxylase genes and transcripts, reagents for screening chemical libraries for lead pharmacological agents, etc.).

DETAILED DESCRIPTION OF THE INVENTION

The nucleotide sequence of natural human and mouse genes encoding natural human

and mouse cholesterol 25-hydroxylase polypeptides are shown as SEQ ID NOS:1 and 3, their natural transcript cDNAs are SEQ ID NO:1, nucleotides 1-1355 and SEQ ID NO:3, nucleotides 1173-2526, respectively, each with an additional 3' polyA tail, and their full translates are shown as SEQ ID NOS:2 and 4, respectively.

The cholesterol 25-hydroxylase polypeptides of the invention include fragments of
5 SEQ ID NOS:2 and 4 having human cholesterol 25-hydroxylase-specific amino acid sequence, binding specificity and function. Preferred polypeptides comprise at least 10, preferably at least 15, more preferably at least 25, more preferably at least 35, most preferably at least 50 consecutive residues of SEQ ID NO:2, wherein such polypeptides and/or consecutive residues are not contained in any conceptual translate of murine ESTs AA289153 and AA285796, nor
10 human ESTs AI081548, W01328, and N45640. The subject domains provide cholesterol 25-hydroxylase domain specific activity or function, such as cholesterol 25-specific hydroxylase or hydroxylase inhibitory activity, SCAP (28) binding or binding inhibitory activity, and/or cholesterol 25-hydroxylase specific antibody binding or binding inhibitory activity.

Cholesterol 25-hydroxylase-specific activity or function may be determined by
15 convenient *in vitro*, cell-based, or *in vivo* assays, e.g. binding assays. The term binding assay is used generically to encompass any assay, including *in vitro*, cell-culture or animal-based assays (e.g. using gene therapy techniques or with transgenics), etc. where the molecular interaction of a cholesterol 25-hydroxylase polypeptide with a specific binding target is evaluated. The binding target may be a natural intracellular binding target such as a cholesterol 25-hydroxylase
20 substrate, a cholesterol 25-hydroxylase regulating protein or other regulator that directly modulates cholesterol 25-hydroxylase activity or its localization; or non-natural binding target such as a specific immune protein such as an antibody, or an cholesterol 25-hydroxylase specific agent such as those identified in screening assays such as described below. Cholesterol 25-hydroxylase-binding specificity may be assayed by hydroxylase activity, hydroxylase
25 activity inhibition (e.g. ability of the subject polypeptides to function as negative effectors in cholesterol 25-hydroxylase-expressing cells), by binding equilibrium constants (usually at least about 10^7 M^{-1} , preferably at least about 10^8 M^{-1} , more preferably at least about 10^9 M^{-1}), by immunogenicity (e.g. ability to elicit cholesterol 25-hydroxylase specific antibody in a heterologous host such as a mouse, rat, goat or rabbit), etc..

30 In a particular embodiment, the subject polypeptides provide cholesterol 25-hydroxylase-specific antigens and/or immunogens, especially when coupled to carrier proteins.

For example, the subject polypeptides are covalently coupled to keyhole limpet antigen (KLH) and the conjugate is emulsified in Freund's complete adjuvant. Laboratory rabbits are immunized according to conventional protocol and bled. The presence of cholesterol 25-hydroxylase-specific antibodies is assayed by solid phase immunosorbent assays using immobilized cholesterol 25-hydroxylase polypeptides of SEQ ID NOS:2 and 4, see, e.g. Table 1.

Table 1. Immunogenic cholesterol 25-hydroxylase polypeptides eliciting cholesterol 25-hydroxylase-specific rabbit polyclonal antibody: cholesterol 25-hydroxylase polypeptide-KLH conjugates immunized per protocol described above.

<u>Cholesterol 25-hydroxylase</u>	<u>Immuno-</u>	<u>Cholesterol 25-hydroxylase</u>	<u>Immuno-</u>
<u>Polypeptide Sequence</u>	<u>genicity</u>	<u>Polypeptide Sequence</u>	<u>genicity</u>
SEQ ID NO:2, res 1-10	+++	SEQ ID NO:4, res 1-24	+++
SEQ ID NO:2, res 6-15	+++	SEQ ID NO:4, res 21-30	+++
SEQ ID NO:2, res 10-20	+++	SEQ ID NO:4, res 31-40	+++
SEQ ID NO:2, res 60-70	+++	SEQ ID NO:4, res 85-109	+++
SEQ ID NO:2, res 62-71	+++	SEQ ID NO:4, res 105-115	+++
SEQ ID NO:2, res 67-76	+++	SEQ ID NO:4, res 110-120	+++
SEQ ID NO:2, res 72-85	+++	SEQ ID NO:4, res 135-144	+++
SEQ ID NO:2, res 81-90	+++	SEQ ID NO:4, res 140-150	+++
SEQ ID NO:2, res 85-95	+++	SEQ ID NO:4, res 145-155	+++
SEQ ID NO:2, res 90-115	+++	SEQ ID NO:4, res 152-163	+++
SEQ ID NO:2, res 116-122	+++	SEQ ID NO:4, res 161-170	+++
SEQ ID NO:2, res 120-128	+++	SEQ ID NO:4, res 168-177	+++
SEQ ID NO:2, res 124-132	+++	SEQ ID NO:4, res 177-186	+++
SEQ ID NO:2, res 130-140	+++	SEQ ID NO:4, res 184-196	+++
SEQ ID NO:2, res 135-152	+++	SEQ ID NO:4, res 193-206	+++
SEQ ID NO:2, res 144-155	+++	SEQ ID NO:4, res 205-211	+++
SEQ ID NO:2, res 154-163	+++	SEQ ID NO:4, res 209-218	+++
SEQ ID NO:2, res 165-174	+++	SEQ ID NO:4, res 215-224	+++
SEQ ID NO:2, res 174-184	+++	SEQ ID NO:4, res 221-229	+++
SEQ ID NO:2, res 183-195	+++	SEQ ID NO:4, res 225-236	+++
SEQ ID NO:2, res 193-206	+++	SEQ ID NO:4, res 230-241	+++

<u>Cholesterol 25-hydroxylase</u>	<u>Immuno-</u>	<u>Cholesterol 25-hydroxylase</u>	<u>Immuno-</u>
<u>Polypeptide Sequence</u>	<u>genicity</u>	<u>Polypeptide Sequence</u>	<u>genicity</u>
SEQ ID NO:2, res 205-211	+++	SEQ ID NO:4, res 236-246	+++
SEQ ID NO:2, res 215-224	+++	SEQ ID NO:4, res 240-249	+++
SEQ ID NO:2, res 225-236	+++	SEQ ID NO:4, res 247-256	+++
SEQ ID NO:2, res 236-246	+++	SEQ ID NO:4, res 251-260	+++
SEQ ID NO:2, res 247-256	+++	SEQ ID NO:4, res 255-265	+++
SEQ ID NO:2, res 255-265	+++	SEQ ID NO:4, res 260-272	+++
SEQ ID NO:2, res 260-272	+++	SEQ ID NO:4, res 267-298	+++

The claimed cholesterol 25-hydroxylase polypeptides are isolated or pure: an "isolated" polypeptide is unaccompanied by at least some of the material with which it is associated in its natural state. Isolated polypeptides encompass cholesterol 25-hydroxylase polypeptides covalently joined to a non-natural or heterologous component, such as a non-natural amino acid or amino acid sequence or a natural amino acid or sequence other than that which the polypeptide is joined to in a natural protein, are preferably in solution, and preferably constitute at least about 0.5%, and more preferably at least about 5% by weight of the total polypeptide in a given sample and pure polypeptides constitute at least about 90%, and preferably at least about 99% by weight of the total polypeptide in a given sample. The polypeptides may be covalently or noncovalently part of a larger complex, such as larger polypeptides and/or various conjugates, etc. The polypeptides may be synthesized, produced by recombinant technology, or purified from mammalian, preferably human cells. A wide variety of molecular and biochemical methods are available for biochemical synthesis, molecular expression and purification of the subject compositions, see e.g. *Molecular Cloning, A Laboratory Manual* (Sambrook, *et al.* Cold Spring Harbor Laboratory), *Current Protocols in Molecular Biology* (Eds. Ausubel, *et al.*, Greene Publ. Assoc., Wiley-Interscience, NY) or that are otherwise known in the art.

The invention provides binding agents specific to the claimed cholesterol 25-hydroxylase polypeptides, including substrates, agonists, antagonists, natural intracellular binding targets, etc., methods of identifying and making such agents, and their use in diagnosis, therapy and pharmaceutical development. For example, specific binding agents are useful in a

variety of diagnostic and therapeutic applications, especially where disease or disease prognosis is associated with unoptimized utilization of a pathway involving one or more of the subject polypeptides, e.g. cholesterol regulation. Novel cholesterol 25-hydroxylase-specific binding agents include cholesterol 25-hydroxylase-specific receptors, such as somatically recombined polypeptide receptors like specific antibodies or T-cell antigen receptors (see, e.g. Harlow and Lane (1988) Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory) and other natural intracellular binding agents identified with assays such as one-, two- and three-hybrid screens, non-natural intracellular binding agents identified in screens of chemical libraries such as in vitro, cell-based and animal-based binding assays described herein, or otherwise known to those of skill in the art, etc. Agents of particular interest modulate cholesterol 25-hydroxylase function, e.g. cholesterol 25-hydroxylase-dependent hydroxylation, and including dominant negative deletion mutants, etc. Accordingly, the invention also provides methods for modulating cholesterol regulation in a cell comprising the step of modulating cholesterol 25-hydroxylase activity, e.g. by contacting the cell with a substrate, agonist or antagonist of a resident cholesterol 25-hydroxylase, a dominant negative cholesterol 25-hydroxylase deletion mutant, or cholesterol 25-hydroxylase polynucleotide (below).

The amino acid sequences of the disclosed cholesterol 25-hydroxylase polypeptides are used to back-translate cholesterol 25-hydroxylase polypeptide-encoding polynucleotides optimized for selected expression systems (Holler et al. (1993) Gene 136, 323-328; Martin et al. (1995) Gene 154, 150-166) or used to generate degenerate primers and probes for use in the isolation of natural cholesterol 25-hydroxylase-encoding nucleic acid sequences (see, e.g. "GCG" software, Genetics Computer Group, Inc, Madison WI). The terms polynucleotide and nucleic acid are used interchangeably to refer to any polymer of nucleotides, without restriction by length. Cholesterol 25-hydroxylase-encoding polynucleotides may be used in cholesterol 25-hydroxylase-expression vectors and incorporated into recombinant host cells, e.g. for expression and screening, transgenic animals, e.g. for functional studies such as the efficacy of candidate drugs for disease associated with cholesterol 25-hydroxylase-modulated cell function, etc.

The invention also provides polynucleotides, e.g. hybridization probes and replication / amplification primers, comprising a cholesterol 25-hydroxylase cDNA specific sequence comprising at least one of SEQ ID NO:1 or 3 and polynucleotides comprising a nucleotide sequence sufficient to effect specific hybridization to SEQ ID NO:1 or 3 and not contained in

any of murine ESTs AA289153 and AA285796, nor human ESTs AI081548, W01328, and N456401, such specifically hybridizing polynucleotides including polynucleotides comprising one or more fragments of SEQ ID NO:1 or 3. Such polynucleotides and fragments are at least 12, preferably at least 24, more preferably at least 48, more preferably at least 96 and most preferably at least 182 nucleotides in length. Demonstrating specific hybridization generally requires stringent conditions, for example, hybridizing in a buffer comprising 30% formamide in 5 x SSPE (0.18 M NaCl, 0.01 M NaPO₄, pH 7.7, 0.001 M EDTA) buffer at a temperature of 42°C and remaining bound when subject to washing at 42°C with 0.2 x SSPE; preferably hybridizing in a buffer comprising 50% formamide in 5 x SSPE buffer at a temperature of 42°C and remaining bound when subject to washing at 42°C with 0.2 x SSPE buffer at 42°C.

Specifically hybridizing polynucleotides are readily identified in convenient gel-based assays; for example, polynucleotides comprising SEQ ID NOS:5-10 are shown to specifically hybridize with SEQ ID NO:1 and/or 3 under the foregoing preferred hybridization conditions. Cholesterol 25-hydroxylase nucleic acids can also be distinguished using alignment algorithms, e.g. nucleic acids having a BLASTn 2.0 (See, <http://www.ncbi.nlm.nih.gov/BLAST/>) bit score of at least 100, preferably at least 200 more preferably at least 400, most preferably at least 800 with a significance of at least e-50, preferably at least e-75, more preferably at least e-100, most preferably at least e-125, using default program settings.

Table 2. Exemplary cholesterol 25-hydroxylase nucleic acids which hybridize with a strand of at least one of SEQ ID NO:1 and 3 under Conditions I and II.

<u>SEQ ID NO:1-Specific</u>	<u>Specific</u>	<u>SEQ ID NO:3-Specific</u>	<u>Specific</u>
<u>Cholesterol 25-hydroxylase</u>	<u>Hybrids</u>	<u>Cholesterol 25-hydroxylase</u>	<u>Hybrids</u>
<u>Polynucleotides</u>		<u>Polynucleotides</u>	
SEQ ID NO:1, nucl 1-36	+	SEQ ID NO:3, nucl 1-32	+
SEQ ID NO:1, nucl 32-68	+	SEQ ID NO:3, nucl 40-70	+
SEQ ID NO:1, nucl 207-230	+	SEQ ID NO:3, nucl 98-124	+
SEQ ID NO:1, nucl 248-282	+	SEQ ID NO:3, nucl 148-182	+
SEQ ID NO:1, nucl 344-376	+	SEQ ID NO:3, nucl 222-256	+
SEQ ID NO:1, nucl 352-386	+	SEQ ID NO:3, nucl 258-286	+
SEQ ID NO:1, nucl 388-424	+	SEQ ID NO:3, nucl 304-327	+
SEQ ID NO:1, nucl 406-431	+	SEQ ID NO:3, nucl 381-416	+
SEQ ID NO:1, nucl 420-446	+	SEQ ID NO:3, nucl 468-499	+

<u>SEQ ID NO:1-Specific</u>	<u>Specific</u>	<u>SEQ ID NO:3-Specific</u>	<u>Specific</u>
<u>Cholesterol 25-hydroxylase</u>	<u>Hybrids</u>	<u>Cholesterol 25-hydroxylase</u>	<u>Hybrids</u>
<u>Polynucleotides</u>		<u>Polynucleotides</u>	
SEQ ID NO:1, nucl 438-469	+	SEQ ID NO:3, nucl 556-583	+
SEQ ID NO:1, nucl 466-500	+	SEQ ID NO:3, nucl 607-635	+
SEQ ID NO:1, nucl 488-522	+	SEQ ID NO:3, nucl 685-717	+
SEQ ID NO:1, nucl 502-532	+	SEQ ID NO:3, nucl 745-775	+
SEQ ID NO:1, nucl 530-570	+	SEQ ID NO:3, nucl 823-854	+
SEQ ID NO:1, nucl 544-568	+	SEQ ID NO:3, nucl 895-922	+
SEQ ID NO:1, nucl 551-578	+	SEQ ID NO:3, nucl 978-1003	+
SEQ ID NO:1, nucl 565-592	+	SEQ ID NO:3, nucl 1049-1082	+
SEQ ID NO:1, nucl 578-603	+	SEQ ID NO:3, nucl 1138-1165	+
SEQ ID NO:1, nucl 589-612	+	SEQ ID NO:3, nucl 1245-1276	+
SEQ ID NO:1, nucl 600-624	+	SEQ ID NO:3, nucl 1280-1312	+
SEQ ID NO:1, nucl 607-638	+	SEQ ID NO:3, nucl 1495-1522	+
SEQ ID NO:1, nucl 630-660	+	SEQ ID NO:3, nucl 1602-1628	+
SEQ ID NO:1, nucl 645-669	+	SEQ ID NO:3, nucl 1686-1716	+
SEQ ID NO:1, nucl 655-680	+	SEQ ID NO:3, nucl 1788-1812	+
SEQ ID NO:1, nucl 662-688	+	SEQ ID NO:3, nucl 1824-1856	+
SEQ ID NO:1, nucl 684-716	+	SEQ ID NO:3, nucl 1922-1952	+
SEQ ID NO:1, nucl 692-722	+	SEQ ID NO:3, nucl 1965-1990	+
SEQ ID NO:1, nucl 718-744	+	SEQ ID NO:3, nucl 2130-2155	+
SEQ ID NO:1, nucl 725-751	+	SEQ ID NO:3, nucl 2402-2425	+
SEQ ID NO:1, nucl 745-772	+	SEQ ID NO:3, nucl 2518-2544	+
SEQ ID NO:1, nucl 760-784	+	SEQ ID NO:3, nucl 2645-2672	+
SEQ ID NO:1, nucl 778-803	+	SEQ ID NO:3, nucl 2760-2784	+
SEQ ID NO:1, nucl 1352-1378	+	SEQ ID NO:3, nucl 2852-2878	+
SEQ ID NO:1, nucl 1380-1406	+	SEQ ID NO:3, nucl 2921-2951	+

The invention also provides regulators of cholesterol 25-hydroxylase gene expression, including natural upstream (5') cholesterol 25-hydroxylase gene transcriptional regulatory

elements. Native cholesterol 25-hydroxylase promoter elements may be truncated and recombined to generate novel cholesterol 25-hydroxylase transcriptional regulatory elements. In a particular embodiment, the invention provides promoters comprising a cholesterol 25-hydroxylase gene specific sequence comprising SEQ ID NO:3, nucleotides 1-1182 and promoters comprising a nucleotide sequence that effects specific hybridization to SEQ ID NO:3, nucleotides 1-1182, provides one or more cholesterol 25-hydroxylase promoter activities and comprises one or more fragments of SEQ ID NO:3, nucleotides 1-1182. Specifically hybridizing polynucleotides are readily identified in convenient gel-based assays; for example, polynucleotides comprising SEQ ID NOS:11-16 are shown to specifically hybridize with SEQ ID NO:3, nucleotides 1-1182 under the foregoing preferred hybridization conditions. Such polynucleotides and fragments are at least 12, preferably at least 24, more preferably at least 48, more preferably at least 96, and most preferably at least 182 nucleotides in length. Generally, such elements comprise one or more cholesterol 25-hydroxylase promoter DNA binding protein and/or transcription factor binding sites, examples of which are provided in Table 3.

Table 3. Cholesterol 25-hydroxylase promoter DNA binding protein (BP) and/or transcription factor (TF) binding sites.

<u>Cholesterol 25-Hydroxylase</u> <u>Promoter Binding Sites</u>	<u>DNA</u> <u>BP / TF</u>	<u>Cholesterol 25-Hydroxylase</u> <u>Promoter Binding Sites</u>	<u>DNA</u> <u>BP / TF</u>
SEQ ID NO:3, nucl 1-8	MZF1	SEQ ID NO:3, nucl 813-823	CP2
SEQ ID NO:3, nucl 1-10	SP1	SEQ ID NO:3, nucl 823-828	SRY
SEQ ID NO:3, nucl 12-19	MZF1	SEQ ID NO:3, nucl 847-859	Oct-1
SEQ ID NO:3, nucl 47-58	HNF-3b	SEQ ID NO:3, nucl 851-857	CdxA
SEQ ID NO:3, nucl 53-59	SRY	SEQ ID NO:3, nucl 853-859	SRY
SEQ ID NO:3, nucl 55-67	C/EBP	SEQ ID NO:3, nucl 865-874	GATA-1
SEQ ID NO:3, nucl 64-70	CdxA	SEQ ID NO:3, nucl 865-874	GATA-2
SEQ ID NO:3, nucl 75-81	SRY	SEQ ID NO:3, nucl 909-921	Oct-1
SEQ ID NO:3, nucl 95-106	HNF3b	SEQ ID NO:3, nucl 913-919	CdxA
SEQ ID NO:3, nucl 133-139	CdxA	SEQ ID NO:3, nucl 936-942	SRY
SEQ ID NO:3, nucl 197-206	GATA-2	SEQ ID NO:3, nucl 936-947	HNF-3b

	<u>Cholesterol 25-Hydroxylase</u> <u>Promoter Binding Sites</u>	<u>DNA</u> <u>BP / TF</u>	<u>Cholesterol 25-Hydroxylase</u> <u>Promoter Binding Sites</u>	<u>DNA</u> <u>BP / TF</u>
	SEQ ID NO:3, nucl 215-224	GATA-1	SEQ ID NO:3, nucl 945-951	SRY
	SEQ ID NO:3, nucl 219-225	CdxA	SEQ ID NO:3, nucl 948-954	CdxA
	SEQ ID NO:3, nucl 265-274	c-Ets	SEQ ID NO:3, nucl 954-965	Ik-2
5	SEQ ID NO:3, nucl 311-320	GATA-2	SEQ ID NO:3, nucl 955-963	Lyf-1
	SEQ ID NO:3, nucl 388-395	MZF1	SEQ ID NO:3, nucl 967-973	CdxA
	SEQ ID NO:3, nucl 407-415	STATx	SEQ ID NO:3, nucl 989-996	MZF1
	SEQ ID NO:3, nucl 420-429	GATA-2	SEQ ID NO:3, nucl 1010-1016	CdxA
	SEQ ID NO:3, nucl 459-466	E2F	SEQ ID NO:3, nucl 1046-1059	C/EBPa
10	SEQ ID NO:3, nucl 464-472	GATA-3	SEQ ID NO:3, nucl 1046-1059	C/EBPb
	SEQ ID NO:3, nucl 464-473	GATA-1	SEQ ID NO:3, nucl 1047-1053	CdxA
	SEQ ID NO:3, nucl 479-485	CdxA	SEQ ID NO:3, nucl 1051-1057	SRY
	SEQ ID NO:3, nucl 586-592	CdxA	SEQ ID NO:3, nucl 1096-1107	CREB
	SEQ ID NO:3, nucl 617-624	E2F	SEQ ID NO:3, nucl 1100-1107	CREB
15	SEQ ID NO:3, nucl 648-656	Lyf-1	SEQ ID NO:3, nucl 1100-1107	CRE-BP
	SEQ ID NO:3, nucl 680-693	p300	SEQ ID NO:3, nucl 1100-1111	CREB
	SEQ ID NO:3, nucl 695-703	v-Myb	SEQ ID NO:3, nucl 1109-1117	MZF1
	SEQ ID NO:3, nucl 745-752	MZF1	SEQ ID NO:3, nucl 1126-1139	C/EBPb
	SEQ ID NO:3, nucl 749-759	deltaE	SEQ ID NO:3, nucl 1132-1141	HSF2
20	SEQ ID NO:3, nucl 757-763	CdxA	SEQ ID NO:3, nucl 1132-1141	HSF1
	SEQ ID NO:3, nucl 781-787	SRY	SEQ ID NO:3, nucl 1144-1153	Sp1
	SEQ ID NO:3, nucl 805-811	CdxA	SEQ ID NO:3, nucl 1147-1154	MZF1
	SEQ ID NO:3, nucl 813-819	SRY		

25 Transcriptional regulatory activity is conveniently assayed in transcriptional reporter assays. For example, Table 4 provides cholesterol 25-hydroxylase gene promoter constructs which can regulate expression of luciferase enzymatic activity in CaPO₄ transfected 293 or HeLa cells. For these assays, cells are harvested 18 hrs post transfection and assayed for luciferase.

30

Table 4. Active Cholesterol 25-hydroxylase promoter constructs.

<u>SEQ ID NO:3-Specific Cholesterol 25-hydroxylase Promoter Constructs</u>	<u>Luciferase Expression</u>
SEQ ID NO:3, nucl 1-1182	++++
SEQ ID NO:3, nucl 12-1182	++++
5 SEQ ID NO:3, nucl 64-1182	++++
SEQ ID NO:3, nucl 197-1182	++++
SEQ ID NO:3, nucl 222-1182	++++
SEQ ID NO:3, nucl 388-1182	++++
SEQ ID NO:3, nucl 464-1182	++++
10 SEQ ID NO:3, nucl 586-1182	++++
SEQ ID NO:3, nucl 695-1182	++++
SEQ ID NO:3, nucl 757-1182	++++
SEQ ID NO:3, nucl 1-320 & 813-1182	++++
SEQ ID NO:3, nucl 1-485 & 853-1182	++++
15 SEQ ID NO:3, nucl 1-693 & 909-1182	++++
SEQ ID NO:3, nucl 1-1172	++++
SEQ ID NO:3, nucl 12-1172	++++
SEQ ID NO:3, nucl 64-1172	++++
SEQ ID NO:3, nucl 197-1172	++++
20 SEQ ID NO:3, nucl 222-1172	++++
SEQ ID NO:3, nucl 388-1172	++++
SEQ ID NO:3, nucl 464-1172	++++
SEQ ID NO:3, nucl 586-1172	++++
SEQ ID NO:3, nucl 695-1172	++++
25 SEQ ID NO:3, nucl 757-1182	++++
SEQ ID NO:3, nucl 1-320 & 813-1172	++++
SEQ ID NO:3, nucl 1-485 & 853-1172	++++
SEQ ID NO:3, nucl 1-693 & 909-1172	++++

30 The subject polynucleotides are of synthetic/non-natural sequences and/or are isolated,
i.e. unaccompanied by at least some of the material with which it is associated in its natural

state, preferably constituting at least about 0.5%, preferably at least about 5% by weight of total polynucleotides present in a given fraction, and usually recombinant, meaning they comprise a non-natural sequence or a natural sequence joined to nucleotide(s) other than that to which it is joined on a natural chromosome. Recombinant polynucleotides comprising the nucleotide sequence of SEQ ID NO:1 or 3, or fragments thereof, contain such sequence or fragment at a terminus, immediately flanked by (i.e. contiguous with) a sequence other than that which it is joined to on a natural chromosome, or flanked by a native flanking region fewer than 10 kb, preferably fewer than 2 kb, which is at a terminus or is immediately flanked by a sequence other than that to which it is joined on a natural chromosome. While the polynucleotides are usually RNA or DNA, it is often advantageous to use polynucleotides comprising other bases or nucleotide analogs to provide modified stability, etc.

The subject nucleic acids find a wide variety of applications including use as translatable transcripts, hybridization probes, PCR primers, diagnostic nucleic acids, etc.; use in detecting the presence of cholesterol 25-hydroxylase genes and gene transcripts and in detecting or amplifying nucleic acids encoding additional cholesterol 25-hydroxylase homologs and structural analogs. In diagnosis, cholesterol 25-hydroxylase hybridization probes find use in identifying wild-type and mutant cholesterol 25-hydroxylase alleles in clinical and laboratory samples. Mutant alleles are used to generate allele-specific oligonucleotide (ASO) probes for high-throughput clinical diagnoses. In therapy, therapeutic cholesterol 25-hydroxylase nucleic acids are used to modulate cellular expression or intracellular concentration or availability of active cholesterol 25-hydroxylase.

For example, cholesterol 25-hydroxylase nucleic acids are used to modulate cellular expression or intracellular concentration or availability of active cholesterol 25-hydroxylase protein. Cholesterol 25-hydroxylase inhibitory nucleic acids are typically antisense: single-stranded sequences comprising complements of the disclosed natural cholesterol 25-hydroxylase transcript sequences. Antisense modulation of the expression of a given cholesterol 25-hydroxylase protein may employ antisense nucleic acids operably linked to gene regulatory sequences. Cells are transfected with a vector comprising a cholesterol 25-hydroxylase sequence with a promoter sequence oriented such that transcription of the gene yields an antisense transcript capable of binding to endogenous cholesterol 25-hydroxylase encoding mRNA. Alternatively, single-stranded antisense nucleic acids that bind to genomic DNA or mRNA encoding cholesterol 25-hydroxylase protein may be administered to the target

cell, in or temporarily isolated from a host, at a concentration that results in a substantial reduction in expression of the targeted protein. An enhancement in cholesterol 25-hydroxylase expression is effected by introducing into the targeted cell type cholesterol 25-hydroxylase nucleic acids that increase the functional expression of the corresponding gene products. Such nucleic acids may be cholesterol 25-hydroxylase expression vectors, vectors that upregulate the functional expression of an endogenous allele, or replacement vectors for targeted modification of endogenous mutant or wild type alleles. Techniques for introducing the nucleic acids into viable cells are known in the art and include retroviral-based transfection, viral coat protein-liposome mediated transfection, etc.

The invention provides efficient methods of identifying agents, compounds or lead compounds for agents active at the level of a cholesterol 25-hydroxylase modulatable cellular function and/or cholesterol 25-hydroxylase gene expression, including transcription. A wide variety of assays for transcriptional modulators or binding agents are provided including labeled *in vitro* ligand binding or hydroxylation assays, immunoassays, cell-based reporter assays, etc. The methods are amenable to automated, cost-effective high throughput screening of chemical libraries for lead compounds. Identified reagents find use in the pharmaceutical industries for animal and human trials; for example, the reagents may be derivatized and rescreened in *in vitro* and *in vivo* assays to optimize activity and minimize toxicity for pharmaceutical development.

A wide variety of assays for cholesterol 25-hydroxylase transcriptional regulators are provided including cell-based transcription reporter assays, gel-based or solid-phase promoter-protein binding assays, etc. In a particular embodiment, cholesterol 25-hydroxylase promoter-luciferase reporter constructs are used to transfect cells such as HeLa cells for cell-based transcription assays. Specifically, HeLa cells are plated onto microtiter plates and used to screen libraries of candidate agents for lead compounds that modulate the transcriptional regulation of the cholesterol 25-hydroxylase gene promoter, as monitored by luciferase expression.

A wide variety of assays for binding agents, i.e. screens for compounds that modulate cholesterol 25-hydroxylase interaction with a natural cholesterol 25-hydroxylase binding target are also provided. These assays employ a mixture of components including a cholesterol 25-hydroxylase polypeptide, which may be part of a fusion product with another polypeptide, e.g. a peptide tag for detection or anchoring, etc. The assay mixtures comprise a natural intracellular

cholesterol 25-hydroxylase binding target. In a particular embodiment, the binding target is a cholesterol 25-hydroxylase substrate, agonist, antagonist or regulator. In the case of polypeptide regulators, one may use portions (e.g. peptides) thereof so long as the portion provides binding affinity and avidity to the subject cholesterol 25-hydroxylase polypeptide conveniently measurable in the assay. The assay mixture also comprises a candidate pharmacological agent. Candidate agents encompass numerous chemical classes, though typically they are organic compounds; preferably small organic compounds and are obtained from a wide variety of sources including libraries of synthetic or natural compounds. A variety of other reagents may also be included in the mixture. These include reagents like, salts, buffers, neutral proteins, e.g. albumin, detergents, protease inhibitors, nuclease inhibitors, antimicrobial agents, etc. may be used. In a preferred embodiment, the mixture is provided as a cell line expressing the cholesterol 25-hydroxylase polypeptide in a regulated fashion, as the TR3202a cells described below, or in a cell extract, wherein cholesterol 25-hydroxylase expression is induced and radiolabeled cholesterol substrate is added to the cells.

The resultant mixture is incubated under conditions whereby, but for the presence of the candidate pharmacological agent, the cholesterol 25-hydroxylase polypeptide specifically binds the cellular binding target, portion or analog with a reference binding affinity. The mixture components can be added in any order that provides for the requisite bindings, and incubations may be performed at any temperature which facilitates optimal binding. Incubation periods are likewise selected for optimal binding but also minimized to facilitate rapid, high-throughput screening. In a preferred embodiment, the binding effects the conversion of the radiolabeled substrate to 25-hydroxycholesterol.

After incubation, the agent-biased binding between the cholesterol 25-hydroxylase polypeptide and one or more binding targets is detected by any convenient way. A variety of methods may be used to detect the change depending on the nature of the product and other assay components, e.g. through optical or electron density, radiative emissions, nonradiative energy transfers, etc. or indirectly detected with antibody conjugates, etc. For the preferred cell- or extract-based cholesterol 25-hydroxylase assays, 'binding' is generally detected by a change in the hydroxylation of a cholesterol 25-hydroxylase substrate, such as the conversion of radiolabeled cholesterol to 25 hydroxycholesterol, e.g. by thin layer chromatography.

A difference in the binding affinity of the cholesterol 25-hydroxylase to the target in the absence of the agent as compared with the binding affinity in the presence of the agent indicates

that the agent modulates the binding of the cholesterol 25-hydroxylase to the cholesterol 25-hydroxylase binding target. Analogously, in the cell-based assay also described below, a difference in cholesterol 25-hydroxylase-dependent transcriptional activation in the presence and absence of an agent indicates the agent modulates cholesterol 25-hydroxylase function. A difference, as used herein, is statistically significant and preferably represents at least a 50%, more preferably at least a 90% difference.

The following experimental section and examples are offered by way of illustration and not by way of limitation.

EXAMPLES

EXPERIMENTAL PROCEDURES: *Abbreviations-* cholesterol, 5-cholesten-3 β -ol; 25-hydroxycholesterol, cholest-5-ene-3 β ,25-diol; 24-hydroxycholesterol, cholest-5-ene-3 β ,24-diol; 27-hydroxycholesterol, cholest-5-ene-3 β ,27-diol; cholestanol, 5 α -cholestan-3 β -ol; epicholesterol, 5-cholesten-3 α -ol; coprostanol, 5 β -cholestan-3 β -ol; desmosterol, 5,24-cholestadien-3 β -ol; sitosterol, 5-cholesten-24 β -ethyl-3 β -ol; 25-oxo-27-noncholesterol, 27-nor-25-oxo-5-cholesten-3 β -ol.

Expression Cloning- Total RNA was prepared from 400 mg of an SREBP-1a transgenic mouse liver (14) using RNA-Stat 60 (Tel-Test, Inc. Friendswood, TX). Poly(A)⁺ RNA was prepared from total RNA by two cycles of chromatography on oligo(dT) (mRNA Purification Kit, Pharmacia, Piscataway, NJ). A size-fractionated, directional cDNA library with *Sal*I and *Not*I cohesive ends at the 5'- and 3'- termini, respectively, was constructed from 4 μ g of poly(A)⁺ RNA using a Superscript Plasmid Kit (Life Technologies, Gaithersburg, MD). Size-fractionated cDNA (> 1.0 kb, 10 ng) was ligated with 50 ng of pCMV6 expression vector (a derivative of pCMV4 (15) containing a *Not*I site in the polylinker) using a protocol and reagents supplied with the Superscript kit. Prior to ligation, the pCMV6 vector (1.2 μ g) was digested for 2 h with 10 units of *Not*I and *Sal*I, respectively, in 30 μ l of 1 x *Sal*I restriction buffer (New England Biolabs, Beverly, MA). The digested plasmid was purified by phenol:chloroform (1:1, v/v) extraction, electrophoresed on a 0.8% agarose gel, and recovered from the gel using a QIAquick Gel Extraction Kit (Qiagen GmbH, Germany).

Plasmid DNA was purified from the ligation reaction by precipitation with ammonium acetate-ethanol and resuspended in 4 μ l of water, of which 1 μ l was used to transform 40 μ l of Electromax *E. coli* DH10B cells (Life Technologies). The transformed bacteria were diluted

into 1000 ml of LB medium containing ampicillin. Aliquots of cells were plated on LB ampicillin plates for calculation of the total number of recombinants. The remainder was divided into 400 pools of 2.5-ml each that were grown to saturation overnight at 37°C. The total number of independent recombinants in the cDNA library was 1.5×10^6 , and each pool contained an average of 3800 recombinants. DNA was prepared from individual pools using a Wizard Miniprep Kit (Promega Inc, Madison, WI). The yield of plasmid DNA from each pool was approximately 25 µg.

Human embryonic kidney 293 cells (ATCC # CRL 1573) were plated on day 0 at a density of 7×10^5 cells/60 mm dish in Medium A (Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum, 100 u/ml penicillin, and 100 µg/ml streptomycin sulfate). On day 1, individual dishes were transfected with a mixture of plasmid DNAs that included pool DNA (5 µg), pCMV-StAR (2 µg), phct1 (2 µg), and pVA-1 (1 µg). The expression plasmid pCMV-StAR contains a full-length cDNA encoding the murine steroidogenic acute regulatory protein (StAR, ref.16). The expression plasmid phct1 contains a full-length cDNA encoding the murine oxysterol 7α-hydroxylase enzyme (17,18). The plasmid pVA1 contains the adenovirus type 5 VAI gene (19). A positive control, in which cells were transfected with 1 ng of a murine sterol 27-hydroxylase expression plasmid diluted into 5 µg of pCMV6 vector alone, was included in every experiment. Aliquots (40 µl) of the transfection lipid pfx-8 (Invitrogen, Carlsbad, CA) dissolved in DMEM containing 15 mM HEPES were added to each plasmid mixture. Cells were incubated with the resulting lipid-DNA mixture in 5 ml of DMEM for 4 h at 37°C, in an atmosphere of 8.8% CO₂. Assay of cholesterol 25-hydroxylase activity was thereafter carried out as described below.

To subdivide the positive pool containing a cholesterol 25-hydroxylase cDNA, an aliquot (40 µl) of Electromax DH10B cells were transformed with 0.5 ng of DNA from the positive primary pool. A portion (0.5%) of the transformation mixture was diluted into 50 ml of LB medium containing ampicillin and divided into 20 pools, each containing ~490 recombinants for secondary screening. DNA was prepared from individual pools and 293 cells were transfected as above, except that 6-well plates were used in place of 60 mm dishes, and amounts of reagents were scaled down accordingly. Tertiary screening was similarly performed except subpools of 50 recombinants were transfected. Quaternary screening was carried out with pools of 10 cDNA isolates derived from a matrix array of individual cDNAs to identify a single cholesterol 25-hydroxylase cDNA.

Measurement of cholesterol 25-hydroxylase activity in whole cells - The transfection medium containing the cationic lipid was aspirated and replaced with 3 ml of Medium B (DMEM containing 10% newborn calf lipoprotein-poor serum, 100 u/ml penicillin, and 100 µg/ml streptomycin sulfate) supplemented with 5 µl of [4-¹⁴C]cholesterol (56.6 mCi/mmol; 0.040 µCi/µl; New England Nuclear, Boston, MA). Cells were incubated for a further 60 h at 37°C in an atmosphere of 8.8% CO₂.

Media from the transfected cells were collected and extracted with 8 ml of chloroform:methanol (2:1, v/v). The organic phase from each sample was taken to dryness under a stream of nitrogen and residues were dissolved in 40 µl aliquots of chloroform:methanol (2:1, v/v) and applied to 20 x 20 cm prescored LK5DF silica gel TLC plates (Whatman, Hillsboro, OR) with preadsorbent layers. The plates were developed in ethyl acetate:toluene (4:6, v/v), and exposed to a Fuji BAS-MP phosphoimager plate overnight. Phosphoimage analysis was then performed on a Fuji BAS1000 apparatus.

Isolation of Human Cholesterol 25-Hydroxylase cDNA - A 372 base pair (bp) expressed sequence tag (EST, GenBank #45640) with high sequence identity to a portion of the murine 25-hydroxylase cDNA was identified by BLAST search. A bacterial strain transformed with a plasmid containing the EST sequence cloned into the pT3T7 vector was obtained from Research Genetics, Inc, Huntsville, AL. Plasmid DNA was prepared and a 245 bp fragment was amplified by the polymerase chain reaction. The thermocycler program consisted of 35 cycles of 94°C/30 sec; 60°C/30 sec; 72°C/30 sec. The amplified cDNA fragment was cloned into pGEM-T Easy (Promega Corp., Madison, WI). The insert was excised from the plasmid with *Eco*RI and used for the preparation of a radiolabeled probe by random octamer priming (Megaprime Labeling Kit, Amersham, Arlington Heights, IL). The probe was used to screen 200,000 plaques of a human lung cDNA library in bacteriophage λ gt10 (Cat # HL3004a, Clontech, Palo Alto, CA) using standard hybridization procedures (20). One positive clone was isolated whose cDNA insert was subcloned into the *Eco*RI sites of pBluescript SK⁺ (Stratagene Corp., La Jolla, CA) and pCMV6, yielding plasmids pBS-h25 and pCMV-h25, respectively.

Gene Mapping - Cholesterol 25-hydroxylase gene sequences were isolated from a murine genomic library prepared from 129SvEv DNA and a human genomic library (Cat. #946204, Stratagene), both in bacteriophage λ FIX II, by screening with full-length cDNA probes corresponding to the murine and human cholesterol 25-hydroxylase cDNAs, respectively, using standard protocols (20). Approximately 600,000 murine and 400,000

human recombinants were screened and one positive clone from each library was identified and purified to homogeneity. The corresponding genomic DNA inserts were excised from the bacteriophage vectors and ligated into the *NotI* site of pBluescript SK⁺, yielding plasmids pBS-mg25 and pBS-hg25, respectively.

5 The chromosomal location of the human cholesterol 25-hydroxylase gene was determined by fluorescent in situ hybridization (FISH) and by polymerase chain reaction amplification of somatic cell and radiation hybrid panel DNAs. FISH mapping was performed by See DNA Biotech, Inc. (Downsview, Ontario, Canada). The bacteriophage λ clone harboring the human 25-hydroxylase gene described above was labeled with biotinylated dATP for use as a FISH probe. Of 100 mitotic figures analyzed, 91 showed
10 hybridization signals on paired sister chromatids corresponding to chromosome 10. Comparison of the signal positions with bands generated by staining with DAPI indicated that hybridization occurred at band q23. Radiation and somatic cell hybrid mapping was performed using DNAs in the Somatic Cell Hybrid Mapping Panel #2 (Coriell Institute of Medical Research, Camden, NJ) and the Stanford G-3 radiation
15 hybrid panel (Research Genetics, Huntsville, AL). The primer pair used for amplification correspond to nucleotides 79-98 and 333-314 of the human gene sequence. The thermocycler program consisted of 35 cycles of 94°C/15 sec; 68°C/30 sec on a Perkin Elmer GeneAmp 9600 machine. Only somatic cell hybrid DNAs containing human chromosome 10 produced a positive amplification signal. Analysis of the radiation hybrid data through the
20 Stanford Genome Center server (rhserver@shgc.stanford.edu) indicated linkage of the cholesterol 25-hydroxylase gene to the SHGC-15188 marker (LOD score = 4.4, cR_1000 = 45.76) on chromosome 10 in the vicinity of band q23.

DNA sequencing and RNA Blotting - DNA sequencing was performed on an ABI Prism 377 sequencer using thermocycler sequencing protocols and fluorescent dye terminators.
25 Contiguous DNA sequences were assembled using MacVector software (IBI-Kodak Corp., New haven, CT) and sequence alignments were generated using a Lasergene software package (DNASTAR, Inc., Madison, WI).

For RNA blotting, a murine multiple tissue RNA blot (Clontech, # 7762-1) was hybridized overnight in 50% formamide hybridization buffer at 42°C with a full-length murine
30 25-hydroxylase cDNA probe using standard procedures (20). The probe was radioactively labeled by random nonamer priming with [³²P]CTP. The blot was washed stringently at 65°C,

in 0.1 x SSC containing 0.1% (w/v) SDS before exposure for 5 days to Kodak X-OMAT AR film at -80°C using an intensifying screen.

Antibodies - An anti-peptide antibody against the sequence corresponding to amino acids 69-83 of the murine cholesterol 25-hydroxylase was raised in rabbits. This sequence was synthesized as a multiple antigen peptide by Bio-Synthesis, Inc. (Lewisville, TX). For the initial immunization, 100 µg of peptide was administered intramuscularly as a dispersion in Freund's complete adjuvant to two New Zealand White male rabbits, 3 months of age. Boosts of 100 µg of antigen in Freund's incomplete adjuvant were given on average every five weeks and bleeds were drawn seven days after the second boost. One of the two resulting antisera, U104, was used here after affinity-purification on peptide antigen columns (21).

Epitope Tagging - To construct an epitope-tagged version of the murine cholesterol 25-hydroxylase enzyme, a cDNA fragment spanning the coding region and having *Bsp*DI and *Xba*I restriction sites at the 5' and 3' ends, respectively, was amplified by the polymerase chain reaction. The template was the plasmid pCMV-m25 and the thermocycler program consisted of 35 cycles of 94°C/30 sec; 57°C/15 sec; 72°C/60 sec. The amplified cDNA fragment was purified on a Centricon-100 column (Amicon Corp., Beverly, MA), digested with *Bsp*DI and *Xba*I, repurified by chromatography on a Centricon-100 column, and ligated into a modified pcDNA3 vector containing a sequence for a C-myc epitope in front of the *Bsp*DI site. The desired recombinant was termed pcDNA3-NH₂-myc-m25. This plasmid encodes a fusion protein in which the sequence containing two tandem copies of a C-myc epitope is linked to the amino terminus of the murine cholesterol 25-hydroxylase protein lacking the initial methionine residue. A similar strategy was used to place tandem C-myc epitopes at the amino terminus of the human cholesterol 25-hydroxylase cDNA, producing the plasmid pcDNA3-NH₂-myc-h25.

A double C-myc epitope was placed at the carboxy-terminus of the murine cholesterol 25-hydroxylase cDNA as follows. An oligonucleotide encoding these epitopes with an *Rsr*II cohesive 5'-end and a blunt 3'-end was formed by annealing phosphorylated oligonucleotide primers as described (22). The annealed duplex was ligated into pCMV-m25 that had been digested with *Eco*47III and *Rsr*II and purified by agarose gel electrophoresis. The resulting plasmid, pCMV-m25-COOH-myc, encodes a protein comprising amino acids 1-267 of the murine cholesterol 25-hydroxylase fused to the two C-myc epitope sequences.

Mutagenesis - Site-directed mutagenesis (23) was carried out using a polymerase chain reaction-based kit (Quik-Change, Stratagene) on the plasmid pCMV-m25. The mutagenic oligonucleotide primers were designed to convert histidine codons at positions 242 and 243 of the murine protein to glutamine codons. Mutagenesis was carried out according to instructions provided by the manufacturer. Plasmid DNA products were subjected to DNA sequence analysis to confirm the presence of the substitution mutations and the absence of spurious mutations. The plasmid containing the desired mutations was named pCMV-m25-HH242QQ.

Measurement of cholesterol 25-hydroxylase activity in cell lysates - On day 0, a derivative of Chinese hamster ovarian cells expressing the polyoma virus middle T antigen (31) (CHOP cells) were plated at a density of 750,000 cells/100 mm dish in Medium C (1:1 (v/v) DMEM: Ham's F12 medium containing 5% fetal calf serum, 100 u/ml penicillin, and 100 µg/ml streptomycin sulfate). On day 1, the cells were transfected with 1.5 µg of pVA-1 and 13.5 µg of pCMV6, pCMV-m25-HH242QQ, or pCMV-m25 per dish for vector, mutant, and wild-type 25-hydroxylase transfections, respectively. 60 µl of pfx-8 lipid was used as a transfection reagent as described above. On day 2, cells were incubated for 1 hour with 2% (w/v) 2-hydroxypropyl-β-cyclodextrin dissolved in a 1:1 solution of DMEM/Ham's F12 medium. The cells were washed once with ice-cold PBS and then harvested in the same buffer using a rubber policeman. After centrifugation at 1000 x g for 5 minutes, the buffer was aspirated and the cell pellet was resuspended in 1 ml of 50 mM potassium phosphate buffer, pH 7.4, containing protease inhibitors (Boehringer Complete Mini, EDTA-free, at the concentration recommended by the supplier). A cell lysate was prepared using a Polytron set at 10,000 rpm, with 3 bursts of 3 seconds each with 30 second intervals between bursts. Incubations were performed at 37°C with 140 µg of cell lysate protein in 50 mM potassium phosphate buffer, pH 7.4, containing 5 mM NADPH. [4-¹⁴C]Cholesterol was added in 4 µl of 45% (w/v) 2-hydroxypropylcyclodextrin in water to a final concentration of 5 µM. The total volume of the incubation was adjusted to 200 µl. After 2 h, reactions were extracted with chloroform-methanol (2:1, v/v) and analyzed by thin layer chromatography.

SREBP Cleavage Assay - Stock cultures of CHO-7 cells, a subline of CHO-K1 cells selected for growth in lipoprotein-deficient serum (25), were maintained in Medium D (1:1 (v/v) DMEM: Ham's F12 medium containing 5% newborn calf lipoprotein-poor serum, 100 U/ml penicillin, and 100 µg/ml streptomycin sulfate). On day 0, cells were plated at a density of 7 x 10⁵ cells/60 mm dish. On day 1, transfections were carried out using 4 µg/dish of the

indicated plasmid DNA and Lipofectamin reagent (Life Technologies) according to the manufacturer's instructions and with modifications as described (26). After transfection, fresh media supplemented with 50 μ M mevalonate, 50 μ M compactin and 0.2% ethanol containing either no sterol or a mixture of sterols (final concentrations of 1 μ g/ml 25-hydroxycholesterol and 10 μ g/ml cholesterol) were added. The cells were returned for 20 h to a 37°C incubator, harvested, and then fractionated into a nuclear extract and a $10^5 \times g$ membrane pellet as described (27). Immunoblot analyses of SREBP-1 and -2 proteins were performed using a SuperSignal Substrate kit (Pierce) and the murine monoclonal antibodies IgG-2A4 and IgG-7D4 (28,29).

Gas-Chromatography-Mass Spectrometry - Six-well plates of CHOP cells were transfected with pCMV-m25 or with vector alone as described above, and incubated for 48 h in Medium D supplemented with 10 μ g/ml cholesterol. Thereafter, media were extracted with chloroform:methanol (2:1, v/v; 5 ml/well), and the organic phase was separated and taken to dryness under a stream of nitrogen. Extracts from 6 wells were combined for subsequent procedures. The samples were purified on Isolute Silica columns (International Sorbent Technology, Mid Glamorgan, UK) and hydroxyl groups were converted to trimethylsilyl ethers as previously described (13).

Gas chromatography mass spectrometry was performed on a Varian 3400 gas chromatograph equipped with an HP-5MS capillary column (30 m x 0.25 mm, 0.25 μ m phase thickness) connected to a Finnigan SSQ700 mass spectrometer. The gas chromatography temperature program was: 180°C for 1 min., followed by a temperature gradient of 10°C/min to 300°C, and a final elution at 300°C for 15 minutes. Helium was used as the carrier gas at an injector valve pressure of 6 psi. Injector and transfer line temperatures were set to 280°C, and the injector was operated in the splitless mode. The machine was operated in the electron ionization mode with electron energy set to 70 eV, and the quadrupole was scanned between m/z 100 - 500 at a rate of 1 scan/1.5 seconds.

Analysis of N-Linked Carbohydrates - To examine the sensitivity of N-linked carbohydrates on cholesterol 25-hydroxylase to endoglycosidase digestion, COS M6 cells were initially plated at a density of 5×10^5 cells/60 mm dish in Medium A on Day 0 of the experiment. On Day 1, one dish each was transfected with 4.5 μ g pCMV-m25, pcDNA3-NH₂-myc-m25, pCMV-m25-COOH-myc, pCMV-h25, or pcDNA3-NH₂-myc-h25, together with 0.5 μ g of pVA1 and 20 μ l of pfx-8 lipid as described above. After transfection, cells were cultured

in Medium B. On day 2, cells were harvested using a rubber policeman, pelleted at 1000 x g, washed with 1 ml of phosphate buffered saline (pH 7.4), and resuspended in 0.2 ml of a buffer containing 10 mM Tris-Cl. pH 8.0 and 1 mM EDTA. Cells were lysed by 20 passages through a 22 gauge needle and aliquots of the lysates (10 μ l, ~40 μ g protein) were treated with endoglycosidase H or peptide N-glycosidase (PNGase) F overnight in a volume of 30 μ l according to the instructions given by the supplier (New England Biolabs, Beverly, MA). One volume of 2 X Laemmli gel loading buffer was then added to each sample, followed by incubation at 100°C for 10 minutes and electrophoresis through a 12% polyacrylamide-SDS gel for 16 h at constant current (10 mA). Separated proteins were electroblotted to PVDF membranes (30), which were incubated with affinity-purified (21) anti-peptide antibody directed against cholesterol 25-hydroxylase (U-104, see above) at 0.8 μ g/ml. A goat anti-rabbit horseradish peroxidase-conjugated antibody (Amersham, Arlington Heights, IL) was used as secondary antibody and visualization was via an ECL Plus kit (Amersham).

Cytochemistry - For indirect immunocytochemistry, COS M6 cells were plated at a density of 4 x 10⁴ cells per well on glass coverslips placed in 6-well dishes containing Medium B. On Day 1, cells were transfected with either a vector alone control (pCMV6) or with pCMV-m25-COOH-myc-m25 or pcDNA3-NH₂-myc-m25. Three μ g of plasmid DNA and 12 μ l of pfx-8 lipid were used per well. After transfection, cells were cultured in Medium B. Indirect immunocytochemistry was then performed with the indicated antibody and lectin probes as follows. Cells were fixed for 30 min with 3% (w/v) paraformaldehyde in Hank's balanced salt solution (pH 7.4). Following fixation, the coverslips were briefly rinsed with PBS (0.1 M phosphate buffer, pH 7.4, 0.15 M NaCl), and free aldehyde groups were quenched by incubation in PBS containing 50 mM NH₄Cl for 30 min. Permeabilization was accomplished by incubation in 0.1% (v/v) Triton X-100 in H₂O for 7 min on ice, followed by rinsing in PBS containing 1% (w/v) bovine serum albumin (blocking buffer) for 30 min at room temperature. Coverslips were incubated with rabbit anti-C-myc IgG (Upstate Biotechnology Inc., 10 μ g/ml in blocking buffer) for 2 h at room temperature. Finally, coverslips were incubated with FITC-goat anti-rabbit IgG (Zymed; 20 μ g/ml in blocking buffer) for 1 h at room temperature. For Golgi compartment staining, rhodamine-labeled wheat germ agglutinin was added during the second antibody incubation at a concentration of 1.25 μ g/ml. Coverslips were washed three times with PBS containing 0.1% BSA after each antibody or lectin incubation. Cells were photographed using a Zeiss Photomicroscope.

Inhibitor Studies - Transfection of CHOP cells was carried out as described above with the following exceptions. Cells were plated on Day 0 at a density of 150,000 cells/well in 6-well plates containing Medium C. On Day 1, cells were transfected with 2.7 µg of the indicated cholesterol 25-hydroxylase expression plasmid and 0.3 µg of pVA-1, using 12 µl of pfx-8 as transfection lipid. After 4 h, the lipid-DNA mixture was removed and 1.5 ml of Medium D was added. In certain experiments, this medium was aspirated and replaced on Day 2 with 1 ml per well of a 20 mg/ml solution of 2-hydroxypropyl-β-cyclodextrin (Sigma) in DMEM/Ham's F12 (1:1) medium and returned to the incubator. The cyclodextrin containing medium was replaced after 1-1.5 h with 1.5 ml of Medium D, and substrate and inhibitors were then added, each in a volume of 4.5 µl of ethanol. The concentration of [4-¹⁴C]cholesterol substrate (specific activity = 26.8 mCi/mmol) was 3 µM. Inhibitors were added to final concentrations of 3, 10 or 30 µM. Cells and/or cells plus medium were harvested at the indicated times, extracted, and the conversion of substrate into [4-¹⁴C]25-hydroxycholesterol product was determined by thin layer chromatography as described above. The inhibitors used were cholesterol (5-cholesten-3β-ol), cholestanol (5α-cholestan-3β-ol), epicholesterol (5-cholesten-3α-ol), coprostanol (5β-cholestan-3β-ol), desmosterol (5,24-cholestadien-3β-ol), β-sitosterol (5-cholesten-24β-ethyl-3β-ol), 25-hydroxycholesterol (cholest-5-ene-3β, 25-diol), and 27-nor-25-oxocholesterol (27-nor-25-oxo-5-cholesten-3β-ol). All steroids were purchased from Steraloids Inc. (Wilton, NH), except cholesterol, which was from Sigma (St. Louis, MO).

Stable cell lines - EcR-CHO cells (Invitrogen), a cell line stably expressing the subunits of the *Drosophila* ecdysone receptor, RXR and VgECR (31) were plated on day 0 at a density of 500,000 cells/100 mm dish in Medium C supplemented with 250 µg/ml zeocin. On day 1, cells were transfected with 5 µg of pIND-m25 using 15 µl of Fugene 6 (Boehringer-Mannheim) according to the instructions of the manufacturer. The plasmid pIND-m25 was constructed by insertion of a full-length mouse 25-hydroxylase cDNA fragment from plasmid pCMV-m25 into the pIND vector (Invitrogen). On day 2, cells were split 1:15 and plated in fresh Medium C supplemented with 250 µg/ml Zeocin and 700 µg/ml geneticin. Cells were refed this medium every second day, and on day 10, groups of five geneticin-resistant colonies were replated in individual wells. Following expansion, cells were tested for cholesterol 25-hydroxylase expression by addition of ponasterone (Invitrogen) to a final concentration of 5 µM (16h), followed by immunoblot analysis of total cell protein. Antibody U104 (affinity-purified) was

used to detect expression of the enzyme as described above. One positive group of cells was selected and subcloned through one additional round to ensure clonality. One of the resulting cell strains, designated TR3102a, which manifest high level expression of cholesterol 25-hydroxylase upon ponasterone induction, and another, designated TR3102g, with no detectable inducible enzyme expression, were selected and maintained as lines. For routine induction experiments, 10 μ M ponasterone was used for the indicated time periods.

Cholesterol biosynthesis - TR3102a and TR3102g cells were plated on day 0 at a density of 250,000 cells/60 mm dish in Medium C containing zeocin and geneticin as above. On day 1, the medium was changed to Medium F (Medium D containing 250 μ g/ml Zeocin, 700 μ g/ml geneticin, and 10 μ M ponasterone). On day 2, 20 μ l of an aqueous solution containing 15 μ Ci of [1,2- 14 C]acetate (American Radiolabeled Chemicals), adjusted with cold acetate to a final mass of 1 μ mol, was added to each dish. The additions were made in a staggered fashion so that all cells were harvested at the same time, corresponding to incubation times of 2, 4, and 6 h, respectively. The total time of induction with ponasterone was 27 h, including the acetate labeling period. Nonsaponifiable lipids were isolated and analyzed by thin layer chromatography as described (32) except that 5 μ Ci of [26, 27- 3 H]25-hydroxycholesterol (New England Nuclear) was used as a standard. Quantification of acetate incorporation into cholesterol was via phosphoimage analysis.

RESULTS: The livers of transgenic mice overexpressing the transcription factor SREBP-1a accumulate large quantities of cholesterol and triglycerides, owing to the overproduction of lipid synthesizing enzymes (14). An analysis of stool lipids by mass spectrometry revealed that these animals also excrete high levels of several oxysterols, including 25-hydroxycholesterol. To isolate cDNAs that encode putative oxysterol synthesizing enzymes from the livers of these transgenic mice, an expression cloning strategy in cultured mammalian cells was conceived and optimized. The basic premise of the screen was to transfect cells with pools of hepatic cDNAs cloned into an expression vector, add [14 C]cholesterol to the medium, and then measure the conversion of this substrate into oxysterols by thin layer chromatography assay. Initially, we used a previously isolated sterol 27-hydroxylase cDNA, whose encoded enzyme converts cholesterol into the oxysterol 27-hydroxycholesterol (15), to optimize assay parameters.

Chromatography studies with oxysterol standards revealed that the separation between cholesterol and some oxysterols was poor on silica gel plates. Furthermore, in control

transfection studies with the sterol 27-hydroxylase expression vector, the strong phosphoimage signal from the substrate often obscured a weaker product signal. To overcome these problems, a cDNA encoding a murine oxysterol 7 α -hydroxylase (18) was cotransfected into the cells. This addition should result in the conversion of oxysterol products to their 7 α -hydroxylated forms. The oxysterol 7 α -hydroxylase also possesses a minor 2-hydroxylase activity against 7 α -hydroxylated sterols (18), thus the formation of 2,7 α -hydroxylated oxysterols was expected. Both of these classes of hydroxylated oxysterols were readily separated from cholesterol by thin layer chromatography. The optimum transfection host (293 cells), transfection method (lipofection with pfx-8 lipid), and transient expression time (60 h) were determined. Further experiments confirmed that the sterol 27-hydroxylase enzyme, which is located in the mitochondria (15), was stimulated two- to three-fold when a cDNA encoding the murine steroidogenic acute regulatory protein was cotransfected into cells (16,33). Finally, addition of the adenovirus VA1 gene, which enhances the translation of mRNAs transcribed from transfected plasmids (19), to the DNA cocktail stimulated expression levels another 1.5-fold. Under these optimized conditions, sterol 27-hydroxylase enzyme activity could be detected over background when the cDNA expression vector was diluted 3,000-5,000-fold.

A library consisting of 1.5×10^6 individual cDNAs was next constructed in a pCMV6 vector using poly(A)⁺ mRNA isolated from an SREBP-1a transgenic mouse liver. Two hundred fifty-five aliquots of ~3,800 individual plasmids from the library were screened using the optimized parameters described above. Data from transfection experiments revealed several positive cDNA pools. In one gel, the pool analyzed in lane 1 did not contain a cDNA encoding a cholesterol metabolizing enzyme. However, the pools analyzed in lanes 2-5 produced low to very low levels of two sterols that migrated more slowly and thus were more hydrophilic than the cholesterol substrate. Additional experiments revealed that the pools analyzed in lanes 2-4 contained sterol 27-hydroxylase cDNAs, whereas that analyzed in lane 5 contained a cholesterol 25-hydroxylase cDNA.

The pool containing the 25-hydroxylase cDNA was progressively subdivided and expressed to isolate a single cDNA. As the purity of the cDNA increased, the level of product generated in the transfected cells also increased to the point that cotransfection of the oxysterol 7 α -hydroxylase cDNA was dispensable. Additional experiments revealed that the cDNA-encoded enzyme was not stimulated by inclusion of the steroidogenic acute activator cDNA, suggesting that it was not a mitochondrial protein. Transfection of the pure cDNA into CHOP

cells produced abundant 25-hydroxylase enzyme activity that increased with time of incubation. The activity was stimulated approximately 10-fold by treatment of transfected cells with 2-hydroxypropyl- β -cyclodextrin. This compound presumably removes endogenous cholesterol from the membranes of the transfected cells that otherwise competes with the exogenously added radiolabeled cholesterol substrate (34).

5 The chemical structure of the oxysterol produced by the isolated cDNA was determined by gas chromatography-electron ionization mass spectrometry. The media from cells transfected with the putative cholesterol 25-hydroxylase cDNA contained a prominent sterol eluting at 23.56 minutes from the gas chromatography column. This sterol was not present in the media of mock-transfected cells. The mass spectrum of the cDNA-generated product was
10 virtually identical to that of an authentic 25-hydroxycholesterol standard.

A search of the DNA data bases revealed a human EST with partial sequence similarity to the murine 25-hydroxylase cDNA. This EST was used to isolate a near full-length cDNA encoding the human 25-hydroxylase as described in Experimental Procedures. Transfection
15 into 293 cells of the human cDNA cloned in a pCMV6 vector produced abundant 25-hydroxylase enzyme activity. This activity was stimulated approximately five-fold by treatment of cells with 2-hydroxypropyl- β -cyclodextrin.

Alignments of the genomic DNA and deduced amino acid sequences of the murine and human cholesterol 25-hydroxylases reveal that the two proteins share 78% sequence identity, while the encoding cDNAs are 82% identical in their translated regions.

20 The predicated molecular weights of the murine and human enzymes are 34,700 and 31,700, respectively. The most notable difference between the two is a 26-amino acid extension at the carboxy-terminus of the murine enzyme that is not present in the human enzyme. Both proteins have three clusters of conserved histidine residues (amino acids 143-147, 157-161, and 238-243 in the murine sequence). Similar clusters of histidine residues are
25 present in a *Pseudomonas* alkane hydroxylase and xylene monooxygenase (35,36), the eukaryotic stearyl-CoA desaturases (37), and the yeast and human C-4 sterol methyl oxidases (38,39). These enzymes are members of a family of proteins that utilize diiron cofactors to catalyze diverse reactions on hydrophobic substrates. Hydropathy analyses of the 25-hydroxylase sequences revealed four conserved regions of extended hydrophobicity that can
30 constitute as many as eight transmembrane domains. The location of the first, second, and fourth of these hydrophobic regions coincided with similar sequences in the *Pseudomonas*

alkane hydroxylase, which contains six transmembrane domains (40).

To determine if the clustered histidine residues were important for enzyme activity, a pair of histidine codons at positions 242 and 243 in the murine protein were changed to glutamine codons by site-directed mutagenesis of the wild type cDNA. The resulting mutant cDNA was transfected into CHOP cells and assayed for expression of the protein and for cholesterol 25-hydroxylase enzyme activity. Mutation of the two histidine residues had no effect on steady state expression levels as judged by immunoblotting but eliminated enzyme activity in transfected cells. Similar results were obtained in a second experiment in which cholesterol 25-hydroxylase enzyme activity was measured in cell lysates rather than in intact cells.

The subcellular localization of cholesterol 25-hydroxylase was assessed in two ways. First, the presence and structure of asparagine-linked carbohydrates were analyzed by endoglycosidase digestion. Expression of murine or human cDNAs in COS cells produced two forms of the enzyme that differed in mass by approximately 3 kDa as judged by immunoblotting. When total membrane proteins from transfected cells were digested with endoglycosidase H or peptide: N-glycosidase F, only a single form of cholesterol 25-hydroxylase was detected that migrated with the lower molecular mass enzyme of untreated cells. These data suggested that cholesterol 25-hydroxylase was present in the membrane fraction of the cell and that some of the molecules were glycosylated with high-mannose, asparagine-linked carbohydrates. In agreement with these results, the sequence of the murine enzyme contains two potential sites for N-linked glycosylation (amino acids 5 and 163), and the human enzyme sequence contains three such sites (amino acids 5, 163, and 189).

The second approach employed immunocytochemistry. Simian COS cells were transfected with the plasmid pCMV-m25-COOH-myc, which encodes a carboxyl-terminal, C-Myc epitope-tagged version of the murine cholesterol 25-hydroxylase. After a transient expression period, cells were permeabilized and recombinant cholesterol 25-hydroxylase detected by indirect immunocytochemistry using a fluorescein-labeled secondary antibody. At the same time, the transfected cells were stained with rhodamine-labeled wheat germ agglutinin (Sigma, #L5266), a lectin that binds to glycoproteins concentrated in the Golgi compartment. Fluorescein signal (green) representing cholesterol 25-hydroxylase was detected in the endoplasmic reticulum and a perinuclear compartment of transfected cells. The perinuclear compartment was identified as the Golgi apparatus based on colocalization with the wheat

germ agglutinin lectin (red rhodamine signal). Similar results were obtained when the C-Myc epitope was placed at the amino-terminus of the expressed murine enzyme.

We next isolated the murine and human cholesterol 25-hydroxylase genes. DNA sequence analysis of the isolated genomic DNAs and comparison to the respective cDNA sequences revealed that both genes lacked introns. This structure was confirmed by Southern blotting analyses of murine and human DNA and by direct amplification of the genes from genomic DNA. Transfection into 293 cells of a plasmid containing the genomic DNA insert from the bacteriophage λ clone that encompassed ~10 kb of 5'-flanking DNA and ~3 kb of 3'-flanking DNA of the human 25-hydroxylase gene resulted in the expression of enzyme activity, which indicated that the isolated gene was not a pseudogene and that requisite regulatory sequences were located close to the coding region. The human gene was localized to chromosome 10q23.3 by somatic and radiation hybrid DNA panel mapping and fluorescence in situ hybridization.

The tissue distribution of the murine cholesterol 25-hydroxylase mRNA was assessed by blot hybridization. Low levels of a 1.5 kb mRNA were present in the heart, lung, and kidney. The mRNA was not detected in the livers of control mice, however it was present in RNA from the liver of the SREBP-1a transgenic mouse used to prepare the original cDNA expression library. RNA blotting experiments using commercially available filters revealed only very low levels of human cholesterol 25-hydroxylase mRNA in 16 different tissues.

The potent regulatory effects of 25-hydroxycholesterol were first observed in assays that measured the suppressive effects of oxysterols on cholesterol synthesis (1,2). To determine if the 25-hydroxycholesterol synthesized by the 25-hydroxylase enzyme could suppress cholesterol synthesis, a line of CHO cells containing an ecdysone-inducible 25-hydroxylase cDNA was isolated as described in Experimental Procedures. These cells, and a control cell line that did not contain the 25-hydroxylase cDNA, were induced with the ecdysone analog ponasterone and the incorporation of [14 C] acetate into cholesterol was measured as a function of time. Induction with ecdysone led to a marked reduction of cholesterol synthesis in cells containing the 25-hydroxylase cDNA but had no effect on this parameter in the control cells.

Experiments were carried out to determine if expression of cholesterol 25-hydroxylase in transfected cells affected the processing of SREBP transcription factors. Cultured CHO-7 cells were transiently transfected with either vector alone or an expression vector containing the murine 25-hydroxylase cDNA. After 24 h, fractions enriched in membrane or nuclear proteins

were prepared from the transfected cells. Equal amounts of protein from each subcellular compartment were separated by gel electrophoresis and the levels of SREBP-1 and -2 were determined by immunoblotting. Mock-transfected cells grown in the absence of sterols to induce SREBP-1 cleavage contained intact, uncleaved SREBP-1 in the membrane fraction and cleaved SREBP-1 in the nuclear fraction. Mock-transfected cells grown in the presence of sterols (cholesterol plus 25-hydroxycholesterol) contained a majority of the immunodetectable SREBP-1 in the membrane fraction. Cells transfected with the 25-hydroxylase cDNA and grown in the absence of sterols contained a majority of SREBP-1 in the membrane fraction even though no exogenous sterols were added, presumably because the 25-hydroxycholesterol produced by the expressed 25-hydroxylase suppressed cleavage of the transcription factor. Similar results were obtained when the processing of SREBP-2 was followed by subcellular fractionation and immunoblotting.

We next tested the ability of different sterols to inhibit cholesterol 25-hydroxylase. In these experiments, 293 cells were transfected with a 25-hydroxylase cDNA, treated with 2-hydroxypropyl- β -cyclodextrin to remove endogenous cholesterol, and then incubated with 3 μ M [14 C]cholesterol and the indicated concentrations of unlabeled inhibitor sterol. The rank order of inhibition for the nine sterols tested was desmosterol > cholestanol > 25-hydroxycholesterol > epicholesterol > sitosterol >> coprostanol = 25-oxo-27-nor-cholesterol. When desmosterol and [14 C]cholesterol were present in equimolar amounts (3 μ M), enzyme activity was decreased by 30%, whereas coprostanol did not inhibit the enzyme at this concentration. The observed inhibition of 25-hydroxylase activity could be due to individual sterols acting as either true inhibitors of the enzyme (i.e., not as substrates) or as competitors of the cholesterol substrate. In the case of desmosterol (5,24-cholestadien-3 β -ol), which can not be 25-hydroxylated due to the Δ^{24} bond, this sterol appears to act as a true inhibitor.

REFERENCES

1. Kandutsch, A. A., and Chen, H. W. (1974) *J. Biol. Chem.* **249**, 6057-6061
2. Brown, M. S., and Goldstein, J. L. (1974) *J. Biol. Chem.* **249**, 7306-7314
3. Björkhem, I., Andersson, O., Diczfalusy, U., Sevastik, B., Xiu, R., Duan, C., and Lund, E. (1994) *Proc. Natl. Acad. Sci. U.S.A.* **91**, 8592-8596
4. Babiker, A., Andersson, O., Lund, E., Xiu, R.-J., Deeb, S., Reshef, A., Leitersdorf, E., Diczfalusy, U., and Björkhem, I. (1997) *J. Biol. Chem.* **272**, 26253-26261
5. Lutjohann, D., Breuer, O., Ahlborg, G., Nennesmo, I., Siden, A., Diczfalusy, U., and

Björkhem, I. (1996) *Proc. Natl. Acad. Sci. USA* **93**, 9799-9804

6. Schwarz, M., Lund, E. G., and Russell, D. W. (1998) *Current Opinion in Lipidology* **9**, 1-6

7. Ishibashi, S., Schwarz, M., Frykman, P. K., Herz, J., and Russell, D. W. (1996) *J. Biol. Chem.* **271**, 18017-18023

5 8. Janowski, B. A., Willy, P. J., Devi, T. R., Falck, J. R., and Mangelsdorf, D. J. (1996) *Nature* **383**, 728-731

9. Lehmann, J. M., Kliewer, S. T., Moore, L. B., Smith-Oliver, T. A., Oliver, B. B., Su, J., Sundseth, S. S., Winegar, D. A., Blanchard, D. E., Spencer, T. A., and Willson, T. M. (1997) *J. Biol. Chem.* **272**, 3137-3140

10 10. Russell, D. W., and Setchell, K. D. R. (1992) *Biochemistry* **31**, 4737-4749

11. Peet, D. J., Turley, S. D., Ma, W., Janowski, B. A., Lobaccaro, J.-M. A., Hammer, R. E., and Mangelsdorf, D. J. (1998) *Cell* **93**, 693-704

12. Brown, M. S., and Goldstein, J. L. (1997) *Cell* **89**, 331-340

13. Dzeletovic, S., Breuer, O., Lund, E., and Diczfalussy, U. (1995) *Anal. Biochem.* **225**, 73-80

14. Shimano, H., Horton, J. D., Hammer, R. E., Shimomura, I., Brown, M. S., and Goldstein, J. L. (1996) *J. Clin. Invest.* **98**, 1575-1584

15 15. Andersson, S., Davis, D. L., Dahlbäck, H., Jörnvall, H., and Russell, D. W. (1989) *J. Biol. Chem.* **264**, 8222-8229

20 16. Stocco, D. M., and Clark, B. J. (1996) *Endocrine Rev.* **17**, 221-244

17. Stapleton, G., Steel, M., Richardson, M., Mason, J. O., Rose, K. A., Morris, R. G. M., and Lathe, R. (1995) *J. Biol. Chem.* **270**, 29739-29745

18. Schwarz, M., Lund, E. G., Lathe, R., Björkhem, I., and Russell, D. W. (1997) *J. Biol. Chem.* **272**, 23995-24001

25 19. Schneider, R. J., and Shenk, T. (1987) *Ann. Rev. Biochem.* **56**, 317-332

20. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989), *Molecular Cloning*, Cold Spring Harbor Laboratory Press, New York, NY

21. Harlow, E., and Lane, D. (1988) *Antibodies, A Laboratory Manual*, Cold Spring Harbor Laboratory Press, New York, NY

30 22. Hua, X., Sakai, J., Ho, Y. K., Goldstein, J. L., and Brown, M. S. (1995) *J. Biol. Chem.* **270**, 29422-29427

23. Smith, M. (1985) *Ann. Rev. Genetics* **19**, 423-462
24. Heffernan, M., and Dennis, J. W. (1991) *Nuc. Acids Res.* **19**, 85-92
25. Metherall, J. E., Goldstein, J. L., Luskey, K. L., and Brown, M. S. (1989) *J. Biol. Chem.* **264**, 15634-15641
26. Rawson, R. B., Zelenski, N. G., Nijhawan, D., Ye, J., Sakai, J., Hasan, M. Z., Chang, T.
5 Y., Brown, M. S., and Goldstein, J. L. (1997) *Mol. Cell* **1**, 47-57
27. Sakai, J., Duncan, E. A., Rawson, R. B., Hua, X., Brown, M. S., and Goldstein, J. L.
(1996) *Cell* **85**, 1037-1046
28. Hua, X., Nohturfft, A., Goldstein, J. L., and Brown, M. S. (1996) *Cell* **87**, 415-426
29. Yang, J., Brown, M. S., Ho, Y. K., and Goldstein, J. L. (1995) *J. Biol. Chem.* **270**,
10 12152-12161
30. Thigpen, A. E., Silver, R. I., Guileyardo, J. M., Casey, M. L., McConnell, J. D., and
Russell, D. W. (1993) *J. Clin. Invest.* **92**, 903-910
31. No, D., Yao, T.P., and Evans, R.M. (1996) *Proc. Natl. Acad. Sci., U.S.A.* **93**, 3346-3351
32. Goldstein, J.L., and Brown, M.S. (1973) *Proc. Natl. Acad. Sci., U.S.A.* **70**, 2804-2808
- 15 33. Sugawara, T., Lin, D., Holt, J. A., Martin, K. O., Javitt, N. B., Miller, W. L., and
Strauss, J. F. Jr. (1995) *Biochemistry* **34**, 12506-12512
34. Kilsdonk, E. P. C., Yancey, P. G., Stoudt, G. W., Bangerter, F. W., Johnson, W. J.,
Phillips, M. C., and Rothblat, G. H. (1995) *J. Biol. Chem.* **270**, 17250-17256
35. Suzuki, M., Hayakawa, T., Shaw, J. P., Rekik, M., and Harayama, S. (1991) *J.*
20 *Bacteriol.* **173**, 1690-1695
36. Kok, M., Oldenhuis, R., van der Linden, M. P. G., Raatjes, P., Kingma, J., van
Lelyveld, P. H., and Witholt, B. (1989) *J. Biol. Chem.* **264**, 5435-5441
37. Shanklin, J., Whittle, E., and Fox, B. G. (1994) *Biochemistry* **33**, 12787-12794
38. Bard, M., Bruner, D. A., Pierson, C. A., Lees, N. D., Bierman, B., Frye, L., Koegel, C.,
25 and Barbuch, R. (1996) *Proc. Natl. Acad. Sci., U.S.A.* **93**, 186-190
39. Li, L., and Kaplan, J. (1996) *J. Biol. Chem.* **271**, 16927-16933
40. van Beilen, J. B., Penninga, D., and Witholt, B. (1992) *J. Biol. Chem.* **267**, 9194-9201
41. Fox, B. G., Shanklin, J., Ai, J., Loehr, T. M., and Sanders-Loehr, J. (1994) *Biochemistry*
33, 12776-12786.

30

All publications and patent applications cited in this specification are herein

incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto

5 without departing from the spirit or scope of the appended claims.

WHAT IS CLAIMED IS:

1. An isolated polypeptide comprising at least 8 consecutive amino acid residues of an amino acid sequence selected from SEQ ID NO:2 and SEQ ID NO:4.
2. A polypeptide according to claim 1 comprising at least 16 consecutive amino acid residues of an amino acid sequence selected from SEQ ID NO:2 and SEQ ID NO:4.
3. A polypeptide according to claim 1 comprising at least 32 consecutive amino acid residues of an amino acid sequence selected from SEQ ID NO:2 and SEQ ID NO:4.
4. A polypeptide according to claim 1 comprising at least 8 consecutive amino acid residues of an amino acid sequence selected from SEQ ID NO:2, residues 130-260 and SEQ ID NO:4, residues 143-268.
5. A polypeptide according to claim 1 comprising at least 16 consecutive amino acid residues of an amino acid sequence selected from SEQ ID NO:2, residues 130-260 and SEQ ID NO:4, residues 143-268.
6. A polypeptide according to claim 1 comprising at least 32 consecutive amino acid residues of an amino acid sequence selected from SEQ ID NO:2, residues 130-260 and SEQ ID NO:4, residues 143-268.
7. A polypeptide according to claim 1 comprising at least 8 consecutive amino acid residues of an amino acid sequence selected from the group consisting of:
 SEQ ID NO:2, residues 1-10; SEQ ID NO:2, residues 6-15; SEQ ID NO:2, residues 10-20;
 SEQ ID NO:2, residues 60-70; SEQ ID NO:2, residues 62-71; SEQ ID NO:2, residues 67-76;
 SEQ ID NO:2, residues 72-85; SEQ ID NO:2, residues 81-90; SEQ ID NO:2, residues 85-95;
 SEQ ID NO:2, residues 90-115; SEQ ID NO:2, residues 116-122; SEQ ID NO:2, residues 120-128;
 SEQ ID NO:2, residues 124-132; SEQ ID NO:2, residues 130-140; SEQ ID NO:2, residues 135-152;
 SEQ ID NO:2, residues 144-155; SEQ ID NO:2, residues 154-163; SEQ ID NO:2, residues 165-174;
 SEQ ID NO:2, residues 174-184; SEQ ID NO:2, residues 183-195; SEQ ID NO:2, residues 193-206;
 SEQ ID NO:2, residues 205-211; SEQ ID NO:2, residues

215-224; SEQ ID NO:2, residues 225-236; SEQ ID NO:2, residues 236-246; SEQ ID NO:2, residues 247-256; SEQ ID NO:2, residues 255-265; SEQ ID NO:2, residues 260-272; SEQ ID NO:4, residues 1-24; SEQ ID NO:4, residues 21-30; SEQ ID NO:4, residues 31-40; SEQ ID NO:4, residues 85-109; SEQ ID NO:4, residues 105-115; SEQ ID NO:4, residues 110-120; SEQ ID NO:4, residues 135-144; SEQ ID NO:4, residues 140-150; SEQ ID NO:4, residues 145-155; SEQ ID NO:4, residues 152-163; SEQ ID NO:4, residues 161-170; SEQ ID NO:4, residues 168-177; SEQ ID NO:4, residues 177-186; SEQ ID NO:4, residues 184-196; SEQ ID NO:4, residues 193-206; SEQ ID NO:4, residues 205-211; SEQ ID NO:4, residues 209-218; SEQ ID NO:4, residues 215-224; SEQ ID NO:4, residues 221-229; SEQ ID NO:4, residues 225-236; SEQ ID NO:4, residues 230-241; SEQ ID NO:4, residues 236-246; SEQ ID NO:4, residues 240-249; SEQ ID NO:4, residues 247-256; SEQ ID NO:4, residues 251-260; SEQ ID NO:4, residues 255-265 ; SEQ ID NO:4, residues 260-272; and SEQ ID NO:4, residues 267-298.

8. A recombinant or isolated polynucleotide encoding a polypeptide comprising at least 8 consecutive amino acid residues of an amino acid sequence selected from SEQ ID NO:2 and SEQ ID NO:4.

9. An isolated or recombinant first polynucleotide comprising a portion which hybridizes with a second polynucleotide consisting of the nucleotide sequence set forth as SEQ ID NO:1 or 3 under the following conditions: hybridization in a buffer comprising 50% formamide in 5 x SSPE buffer at a temperature of 42°C and remaining bound when subject to washing at 42°C with 0.2 x SSPE buffer at 42°C, said portion comprising a nucleotide sequence not contained in any of murine ESTs AA289153 and AA285796, nor human ESTs AI081548, W01328, and N456401.

10. A polynucleotide according to claim 9, wherein said portion does not hybridize with said murine EST and human ESTs under said hybridization conditions.

11. An isolated or recombinant polynucleotide comprising at least 24 consecutive nucleotides of a nucleotide sequence selected from SEQ ID NO:1, nucleotides 1-60; SEQ ID NO:1, nucleotides 196-240; SEQ ID NO:1, nucleotides 240-300; SEQ ID NO:1, nucleotides

350-800; SEQ ID NO:1, nucleotides 1340-1406; SEQ ID NO:3, nucleotides 1-1190; SEQ ID NO:3, nucleotides 1230-1260; SEQ ID NO:3, nucleotides 1260-1300; SEQ ID NO:3, nucleotides 1490-1530; SEQ ID NO:3, nucleotides 1590-1970; SEQ ID NO:3, nucleotides 1970-2000; SEQ ID NO:3, nucleotides 2126-2166; and SEQ ID NO:3, nucleotides 2380-2951.

- 5 12. A polynucleotide according to claim 11, comprising at least 24 consecutive nucleotides of a nucleotide sequence selected from the SEQ ID NO:1, nucleotides 1-36; SEQ ID NO:1, nucleotides 32-68; SEQ ID NO:1, nucleotides 207-230; SEQ ID NO:1, nucleotides 248-282; SEQ ID NO:1, nucleotides 344-376; SEQ ID NO:1, nucleotides 352-386; SEQ ID NO:1, nucleotides 388-424; SEQ ID NO:1, nucleotides 406-431; SEQ ID NO:1, nucleotides 420-446;
- 10 SEQ ID NO:1, nucleotides 438-469; SEQ ID NO:1, nucleotides 466-500; SEQ ID NO:1, nucleotides 488-522; SEQ ID NO:1, nucleotides 502-532; SEQ ID NO:1, nucleotides 530-570; SEQ ID NO:1, nucleotides 544-568; SEQ ID NO:1, nucleotides 551-578; SEQ ID NO:1, nucleotides 565-592; SEQ ID NO:1, nucleotides 578-603; SEQ ID NO:1, nucleotides 589-612; SEQ ID NO:1, nucleotides 600-624; SEQ ID NO:1, nucleotides 607-638; SEQ ID NO:1,
- 15 nucleotides 630-660; SEQ ID NO:1, nucleotides 645-669; SEQ ID NO:1, nucleotides 655-680; SEQ ID NO:1, nucleotides 662-688; SEQ ID NO:1, nucleotides 684-716; SEQ ID NO:1, nucleotides 692-722; SEQ ID NO:1, nucleotides 718-744; SEQ ID NO:1, nucleotides 725-751; SEQ ID NO:1, nucleotides 745-772; SEQ ID NO:1, nucleotides 760-784; SEQ ID NO:1, nucleotides 778-803; SEQ ID NO:1, nucleotides 1352-1378; SEQ ID NO:1, nucleotides 1380-
- 20 1406; SEQ ID NO:3, nucleotides 1-32; SEQ ID NO:3, nucleotides 40-70; SEQ ID NO:3, nucleotides 98-124; SEQ ID NO:3, nucleotides 148-182; SEQ ID NO:3, nucleotides 222-256; SEQ ID NO:3, nucleotides 258-286; SEQ ID NO:3, nucleotides 304-327; SEQ ID NO:3, nucleotides 381-416; SEQ ID NO:3, nucleotides 468-499; SEQ ID NO:3, nucleotides 556-583; SEQ ID NO:3, nucleotides 607-635; SEQ ID NO:3, nucleotides 685-717; SEQ ID NO:3,
- 25 nucleotides 745-775; SEQ ID NO:3, nucleotides 823-854; SEQ ID NO:3, nucleotides 895-922; SEQ ID NO:3, nucleotides 978-1003; SEQ ID NO:3, nucleotides 1049-1082; SEQ ID NO:3, nucleotides 1138-1165; SEQ ID NO:3, nucleotides 1245-1276; SEQ ID NO:3, nucleotides 1280-1312; SEQ ID NO:3, nucleotides 1495-1522; SEQ ID NO:3, nucleotides 1602-1628; SEQ ID NO:3, nucleotides 1686-1716; SEQ ID NO:3, nucleotides 1788-1812; SEQ ID NO:3,
- 30 nucleotides 1824-1856; SEQ ID NO:3, nucleotides 1922-1952; SEQ ID NO:3, nucleotides 1965-1990; SEQ ID NO:3, nucleotides 2130-2155; SEQ ID NO:3, nucleotides 2402-2425;

SEQ ID NO:3, nucleotides 2518-2544; SEQ ID NO:3, nucleotides 2645-2672; SEQ ID NO:3, nucleotides 2760-2784; SEQ ID NO:3, nucleotides 2852-2878; and SEQ ID NO:3, nucleotides 2921-2951.

13. A polynucleotide according to claim 11, wherein the polynucleotide comprises a recombinant regulator of gene expression comprising the cholesterol 25-hydroxylase promoter of SEQ ID NO:3, nucleotides 1-1182, or a deletion mutant thereof at least 50 nucleotides in length having cis transcriptional regulatory activity.

14. A polynucleotide according to claim 11, wherein the polynucleotide comprises a recombinant regulator of gene expression comprising the cholesterol 25-hydroxylase promoter of SEQ ID NO:3, nucleotides 1-1182, or a deletion mutant thereof at least 50 nucleotides in length having cis transcriptional regulatory activity and said mutant comprises at least one binding site from Table 4.

15. A polynucleotide according to claim 11, wherein the polynucleotide comprises a recombinant regulator of gene expression comprising the cholesterol 25-hydroxylase promoter of SEQ ID NO:3, nucleotides 1-1182, or a deletion mutant thereof at least 50 nucleotides in length having cis transcriptional regulatory activity, and comprises a non-cholesterol 25-hydroxylase core promoter operatively joined to said mutant.

16. A polynucleotide according to claim 11, wherein the polynucleotide comprises a recombinant regulator of gene expression comprising the cholesterol 25-hydroxylase promoter of SEQ ID NO:3, nucleotides 1-1182, or a deletion mutant thereof at least 50 nucleotides in length having cis transcriptional regulatory activity, and comprises a reporter gene other than a cholesterol 25-hydroxylase gene operatively joined to said regulator.

17. A cell comprising a polynucleotide according to claim 8.

18. A cell comprising a polynucleotide according to claim 11.

19. A cell comprising a regulator according to claim 13 operably linked to a non-cholesterol

25-hydroxylase reporter gene.

20. A method of making an isolated polypeptide comprising SEQ ID NO:2 or 4, or at least a 25 residue fragment thereof, said method comprising steps: introducing a polynucleotide according to claim 8 into a host cell or cellular extract, incubating said host cell or extract under conditions whereby said polynucleotide is expressed as a transcript and said transcript is expressed as a translation product comprising said polypeptide, and isolating said translation product.

21. A method of screening for an agent that modulates the interaction of a cholesterol 25-hydroxylase polypeptide to a binding target, said method comprising the steps of:

incubating a mixture comprising:

an isolated polypeptide according to claim 1,

a binding target of said polypeptide, and

a candidate agent;

under conditions whereby, but for the presence of said agent, said polypeptide specifically binds said binding target at a reference affinity;

detecting the binding affinity of said polypeptide to said binding target to determine an agent-biased affinity,

wherein a difference between the agent-biased affinity and the reference affinity indicates that said agent modulates the binding of said polypeptide to said binding target.

22. A method of screening for an agent that modulates the interaction of a cholesterol 25-hydroxylase polypeptide to a binding target, said method comprising the steps of:

incubating a polynucleotide according to claim 9 under conditions whereby the polypeptide is expressed;

incubating a mixture comprising said polypeptide, a binding target of said polypeptide, and a candidate agent under conditions whereby, but for the presence of said agent, said polypeptide specifically binds said binding target at a reference affinity;

detecting the binding affinity of said polypeptide to said binding target to determine an agent-biased affinity,

wherein a difference between the agent-biased affinity and the reference affinity

indicates that said agent modulates the binding of said polypeptide to said binding target.

23. A method according to claim 22, wherein said polynucleotide is in a cell.

24. A method according to claim 22, wherein said polynucleotide is in a cell and said
5 mixture is in said cell.

25. A method according to claim 22, wherein said polynucleotide is in a cell, said mixture
is in said cell and said binding target comprises cholesterol.

26. A method according to claim 22, wherein said polynucleotide is in a cell, said mixture
10 is in said cell, said binding target comprises cholesterol and said detecting comprises detecting
the conversion of said cholesterol into 25-hydroxy cholesterol.

27. A method for identifying an agent that modulates the association of a cholesterol 25-
15 hydroxylase promoter and a transcription factor, said method comprising steps:
combining a polynucleotide according to claim 13, a transcription factor and a
candidate agent, under conditions wherein, but for the presence of said agent, said regulator and
said transcription factor form a first association;

20 detecting the presence of a second association of said regulator and said transcription
factor;

wherein a difference between said first and said second association indicates said agent
modulates the association of a cholesterol 25-hydroxylase promoter and said transcription
factor.

28. A method for identifying an agent that regulates the activity of a cholesterol 25-
25 hydroxylase promoter, said method comprising steps:

contacting a cell according to claim 19 with a candidate agent, under conditions
wherein, but for the presence of said agent, said reporter gene exhibits a first expression;

detecting the presence of a second expression of said reporter gene;

30 wherein a difference between said first and said second expression indicates said agent
regulates the activity of a cholesterol 25-hydroxylase gene promoter.

29. A method according to claim 28, wherein said detecting step comprises detecting a colorimetric or luminescent signal of a gene product of said reporter gene.

30. A method according to claim 28 wherein said gene is detected by hybridization to a nucleic acid specific for said gene.

SEQUENCE LISTING

5 <110> Russel, David W
 Lund, Erik G
 <120> Cholesterol 25-Hydroxylase
 <130> UTSD1370
 10 <140>
 <141>
 <160> 16
 15 <170> PatentIn Ver. 2.0
 <210> 1
 <211> 1406
 <212> DNA
 20 <213> human
 <220>
 <221> CDS
 <222> (11)..(826)
 25 <400> 1
 cagcctcgca atg agc tgc cac aac tgc tcc gac ccc cag gtc ctt tgc 49
 Met Ser Cys His Asn Cys Ser Asp Pro Gln Val Leu Cys
 1 5 10
 30 agc tcc ggg cag ctg ttc ctg cag ccc ctc tgg gac cac ctg agg agc 97
 Ser Ser Gly Gln Leu Phe Leu Gln Pro Leu Trp Asp His Leu Arg Ser
 15 20 25
 35 tgg gag gcc ctc cta cag tgc ccc ttc ttc ccg gtc atc ttc tcc atc 145
 Trp Glu Ala Leu Leu Gln Ser Pro Phe Phe Pro Val Ile Phe Ser Ile
 30 35 40 45
 40 acc aca tac gtg ggc ttt tgc ctg ccc ttc gtg gtc ctg gat atc ctg 193
 Thr Thr Tyr Val Gly Phe Cys Leu Pro Phe Val Val Leu Asp Ile Leu
 50 55 60
 45 tgc tcc tgg gtg ccc gcc ctg cgg cgc tac aag atc cac cct gac ttc 241
 Cys Ser Trp Val Pro Ala Leu Arg Arg Tyr Lys Ile His Pro Asp Phe
 65 70 75
 50 tgc cca tcc gcg cag cag ctg cta cct tgc ctg ggg cag acc ctc tac 289
 Ser Pro Ser Ala Gln Gln Leu Leu Pro Cys Leu Gly Gln Thr Leu Tyr
 80 85 90
 55 cag cat gtg atg ttt gtg ttc ccc gtg acg ctg ctg cat tgg gcc cgc 337
 Gln His Val Met Phe Val Phe Pro Val Thr Leu Leu His Trp Ala Arg
 95 100 105
 60 agc ccg gcc ctc ctg ccc cac gaa gct ccc gag ctg ctc ctg ctg ctg 385
 Ser Pro Ala Leu Leu Leu His Glu Ala Pro Glu Leu Leu Leu Leu
 110 115 120 125
 65 cac cac atc ctg ttc tgc ctg cta ctc ttc gac atg gag ttc ttc gtg 433
 His His Ile Leu Phe Cys Leu Leu Leu Phe Asp Met Glu Phe Phe Val
 130 135 140
 tgg cac ctg ctg cac cac aag gtg ccc tgg ctg tac cgc acc ttc cac 481
 Trp His Leu Leu His His Lys Val Pro Trp Leu Tyr Arg Thr Phe His
 145 150 155

aag gtg cac cac cag aac tcg tcc tcg ttc gcg ctg gca acg cag tat 529
 Lys Val His His Gln Asn Ser Ser Ser Phe Ala Leu Ala Thr Gln Tyr
 160 165 170

5 atg agc gtc tgg gaa ctg ttt tct ttg ggc ttc ttc gac atg atg aac 577
 Met Ser Val Trp Glu Leu Phe Ser Leu Gly Phe Phe Asp Met Met Asn
 175 180 185

10 gtc aca ctg ctc ggg tgc cac ccg ctc acc acc ctg acc ttc cac gtg 625
 Val Thr Leu Leu Gly Cys His Pro Leu Thr Thr Leu Thr Phe His Val
 190 195 200 205

15 gtc aac atc tgg ctt tcc gtg gag gac cac tcc ggc tac aac ttc cct 673
 Val Asn Ile Trp Leu Ser Val Glu Asp His Ser Gly Tyr Asn Phe Pro
 210 215 220

20 tgg tcc act cac aga ctg gtg ccc ttc ggg tgg tac ggg ggt gtg gtg 721
 Trp Ser Thr His Arg Leu Val Pro Phe Gly Trp Tyr Gly Gly Val Val
 225 230 235

cac cac gac ctg cat cac tct cac ttt aac tgc aac ttc gct ccg tac 769
 His His Asp Leu His His Ser His Phe Asn Cys Asn Phe Ala Pro Tyr
 240 245 250

25 ttt aca cac tgg gac aaa ata ctg gga acg ctg cgg act gca tct gtc 817
 Phe Thr His Trp Asp Lys Ile Leu Gly Thr Leu Arg Thr Ala Ser Val
 255 260 265

30 cca gcg cgg tgatgtggct gcgggtgggtg cccctaagac tcgggactgc 866
 Pro Ala Arg
 270

35 tgtgcctttc acacttgaat gaagagaaac acctgagcta tatatTTTTT taaagcaact 926
 aacttattgc tttatgttta tctatgaaaa ccatagataa aatctgatgc atttttgtaa 986
 tctgacaaag taatttacat actgtttgtg tatcaataca attttgtgtt cttggtattc 1046

40 ttagtctagc tcacctcaat agccttgaat cctgcatatg aattagacat tcatcactgg 1106
 catattttaga atatctctaa aaggacttgt ttgtagaata aggaattttc tatgtttcaa 1166
 agtgttctaa aacctggcta aaagaatgta tttttgtgga tgggtgttgac ttctgactct 1226

45 aaaagcaatc aaacatgttt ctgctggaca gtgaccaaga attatagtac cttcttatat 1286
 ttttttatag aactgtatat ttattttgaa agaaatgtta ttcgtgcttt aaaaaggaaa 1346
 aaaaaccatg aatcaaataa gtattgactt ccgtttcact ggtattttga ctgataaaaa 1406

50 <210> 2
 <211> 272
 <212> PRT
 <213> human

55 <400> 2
 Met Ser Cys His Asn Cys Ser Asp Pro Gln Val Leu Cys Ser Ser Gly
 1 5 10 15

60 Gln Leu Phe Leu Gln Pro Leu Trp Asp His Leu Arg Ser Trp Glu Ala
 20 25 30

65 Leu Leu Gln Ser Pro Phe Phe Pro Val Ile Phe Ser Ile Thr Thr Tyr
 35 40 45

3

4

	135	140	145	
5	gtg ccc tgg ctg tac cgc acc ttc cac aag gtg cat cac cag aac tcg Val Pro Trp Leu Tyr Arg Thr Phe His Lys Val His His Gln Asn Ser 150 155 160	1674		
10	tcc tcc ttc gcg ctg gcg acc caa tac atg agc ttc tgg gag ctg ctt Ser Ser Phe Ala Leu Ala Thr Gln Tyr Met Ser Phe Trp Glu Leu Leu 165 170 175	1722		
15	tcg ctg acc ttc ttc gac gtg ctg aac gtc gcg gtg ctt cgg tgt cac Ser Leu Thr Phe Phe Asp Val Leu Asn Val Ala Val Leu Arg Cys His 185 190	1770		
20	cca ctc acc atc ttt acc ttt cac gtg att aac atc tgg ctg tcg gtg Pro Leu Thr Ile Phe Thr Phe His Val Ile Asn Ile Trp Leu Ser Val 200 205	1818		
25	gag gac cac tcg ggc tat gac ttc ccg tgg tcc act cac aga ctt gtg Glu Asp His Ser Gly Tyr Asp Phe Pro Trp Ser Thr His Arg Leu Val 215 220 225	1866		
30	ccc ttt ggc tgg tac ggg ggc gtg gct cac cac gac atg cat cac tct Pro Phe Gly Trp Tyr Gly Gly Val Ala His His Asp Met His His Ser 230 235 240	1914		
35	cag ttt aac tgc aat ttt gct cct tac ttc aca cac tgg gac aaa atg Gln Phe Asn Cys Asn Phe Ala Pro Tyr Phe Thr His Trp Asp Lys Met 245 250 255 260	1962		
40	ctg ggc act ctg cgg tcc gcg ccc ctg cca gag agc ctt tgc gcc tgc Leu Gly Thr Leu Arg Ser Ala Pro Leu Pro Glu Ser Leu Cys Ala Cys 265 270 275	2010		
45	ggt gag cgc tgc gtg aac tcc aga gag cga tgc gct gta cac ttg atc Gly Glu Arg Cys Val Asn Ser Arg Glu Arg Cys Ala Val His Leu Ile 280 285 290	2058		
50	cag aag aag aaa cag act tgagttactt tattagaagt ttgtaacttt Gln Lys Lys Lys Gln Thr	2106		
55	taaagtgatg cacactgcta taaaatctaa tgttggttttt gcagcctgac aaagtaattt atataatgtt tctatgtgaa ttttaattgtg gtcttggtgt taaatttcaa cttatcccag tgtcattgac tccaggacac aaggtagaca ttcagcgtgg tgtatttgaa tcattatgat ntctgaaatg atttgtttct agaaccaaga ctttcctatg tatgaaatcg cactggaact gggctctaac ctccatgtt gagagaagac ctgatttctg actctttaa taatcaaatt tgttctctgct gggcagtgac caaggttata gtatattttt tctacttttg aatgaaatga tatattttata ttgaaaaaag ttttatttgt attttaaaaa taaaaagaac atgaactaaa caagcattag ctcttggtgg gctgatgaa ttaaaaaaaa aactaaaaag gaagtgtgtg tgtgtgtgtg tgtgtgtgtg tgtgtgtgtg tgtgtgtgtg tctgaggctt ctcaagtgtt tttgaaacat ctaccactct tgccatggca aaaacaattt ggtgcatgt attgggcggg ggggctaggg aataactttg ggaanaagct aggggctact gactgcttat tcccactgct ttttgtctgg ttttgacata aaaaccctg aaaaaccgct ctgtangtta ctttnctang	2166 2226 2286 2346 2406 2466 2526 2586 2646 2706 2766 2826		

ggannaanaa cactctcttc tgtattgttg gantgctatg cgtagggtaa ctaaaaatca 2886
 naattncccc ttgataaccc atttagtgca ttagggaaac tgaaaaacac cccattttta 2946
 5 aggggt 2951

<210> 4
 <211> 298
 <212> PRT
 <213> Mouse

<400> 4
 15 Met Gly Cys Tyr Asn Gly Ser Glu Leu Gln Asp Leu Gly Cys Ser Ser
 1 5 10 15
 Gln Leu Leu Leu Gln Pro Leu Trp Asp Thr Ile Arg Thr Arg Glu Ala
 20 25 30
 20 Phe Thr Arg Ser Pro Ile Phe Pro Val Thr Phe Ser Ile Ile Thr Tyr
 35 40 45
 Val Gly Phe Cys Leu Pro Phe Val Val Leu Asp Val Leu Tyr Pro Trp
 50 55 60
 25 Val Pro Ile Leu Arg Arg Tyr Lys Ile His Pro Asp Phe Ser Pro Ser
 65 70 75 80
 30 Val Lys Gln Leu Leu Pro Cys Leu Gly Leu Thr Leu Tyr Gln His Leu
 85 90 95
 Val Phe Val Phe Pro Val Thr Leu Leu His Trp Val Arg Ser Pro Ala
 100 105 110
 35 Leu Leu Pro Gln Glu Ala Pro Glu Leu Val Gln Leu Leu Ser His Val
 115 120 125
 Leu Ile Cys Leu Leu Leu Phe Asp Thr Glu Ile Phe Ala Trp His Leu
 130 135 140
 40 Leu His His Lys Val Pro Trp Leu Tyr Arg Thr Phe His Lys Val His
 145 150 155 160
 45 His Gln Asn Ser Ser Ser Phe Ala Leu Ala Thr Gln Tyr Met Ser Phe
 165 170 175
 Trp Glu Leu Leu Ser Leu Thr Phe Phe Asp Val Leu Asn Val Ala Val
 180 185 190
 50 Leu Arg Cys His Pro Leu Thr Ile Phe Thr Phe His Val Ile Asn Ile
 195 200 205
 Trp Leu Ser Val Glu Asp His Ser Gly Tyr Asp Phe Pro Trp Ser Thr
 210 215 220
 55 His Arg Leu Val Pro Phe Gly Trp Tyr Gly Gly Val Ala His His Asp
 225 230 235 240
 60 Met His His Ser Gln Phe Asn Cys Asn Phe Ala Pro Tyr Phe Thr His
 245 250 255
 Trp Asp Lys Met Leu Gly Thr Leu Arg Ser Ala Pro Leu Pro Glu Ser
 260 265 270
 65 Leu Cys Ala Cys Gly Glu Arg Cys Val Asn Ser Arg Glu Arg Cys Ala
 275 280 285

Val His Leu Ile Gln Lys Lys Lys Gln Thr
 290 295

5
 <210> 5
 <211> 36
 <212> DNA
 <213> Artificial Sequence

10
 <220>
 <223> Description of Artificial Sequence: Synthetic Sequence

15
 <400> 5
 cgtcgcgctg cttcgggtgc acccactcac catctt 36

20
 <210> 6
 <211> 1106
 <212> DNA
 <213> Artificial Sequence

25
 <220>
 <223> Description of Artificial Sequence: Synthetic Sequence

30
 <400> 6
 acacaacctt gtataagact atgtttagctt ccagcagaga aaagcagctg taaagacaca 60
 aattcaagaa ggaaaccctg ggagaatggc ccctggcttt cctctgggat cttctgtgcc 120
 gtgtatccgc taccggtggc tgattttctgt gctccactgt ctagggcact ctccttggat 180

35
 atagtactga ctcctgtgc tcagtccttg gacgatcagt ccagtggtct gaaagggat 240
 ccaggagttg aggagtaggg aacaactgag gggttggtaaa agtcggagcc tgagggacct 300

40
 ctaaggaaat cgcaggggag atgagacatg ttccgggagg ctatgagatt gtcagatct 360
 tcttctccac tggcctttgc ggtttggccc aatcgagtga gcctttacgg gtgttaagcc 420
 tccgttctcc aaccagagc aaaggctggc agtgctgccc tcttgaccgc tgtcttgacg 480

45
 gatctgatct ctgctcttga caccgctggc tttaagggca ccagagcggg agagtcgtcc 540
 gcgccaaaag gctgcgagcc tgactgctct tttttggagg atgccagggt ccctctccta 600

50
 caggactcaa tcccagtcctg caacggaccc agtaccagca ctgtggcgtg aggtacgcac 660
 actcagagtc cccaaggtg tagaataagt ctttaaagcag tcaaaaacag atatttttaa 720
 acccagggaa ttctgctttg gttgagaaac agcgccttct gagagcgaag aactcattag 780

55
 tttttagcgg tgatggcggg tgaactgtcc caaggcagaa tcgctctctc ctgtgtcatt 840
 agtacatcag ctgaaaggca agcaaacagt tctttacgtc tgggaaaggg ctttaaggcc 900

60
 cgctgcttgc gtgaagggca gatttgatgc agctataaac caggacatag acaggaacaa 960
 aattcgggtt atttaagcaa aattcttttag cagggaaagg gaggtgggaa ggagacggaa 1020
 gggtgacgtc actgggggga gtggccacag tcttaagaaa agtcggcggg cctggggaga 1080

65
 ccacaattgt gggacatagt ctcagc 1106

<210> 7
 <211> 1030
 <212> DNA

5 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Sequence

10

<400> 7

cctgggagaa tggcccttgg ctttcctcag ggatcttctg tgccgtgtat ccgctacccg 60
 gggctgattt ctgtgctcca ctctctaggg cactctcctt ggatatagta ctgacctcct 120
 15 gtgctcagtc cctggacgat cagtcccagt gtctgaaagg gtatccagga gttgaggagt 180
 agggaaacaac tgagggttgg taaaagtcgg agcctgaggg acctctaagg aaatggcagg 240
 20 ggagatgaga catgttgagg gaggctatga gattgctcag atcttcttct ccactggcct 300
 ttgcggtttg gcccaatcga gtgagccttt acgggtgtta agcctccgtt ctccaaccca 360
 gagcaaaggc tggcagtgtc gccctcttga ccgctgtctt gcaggatctg atctctgctc 420
 25 ttgacaccgc gggctttaag ggcaccagag cgggagagtc gtccgcgcca aaaggctgcy 480
 agccagactg ctcttttttg gaggatgcca ggttccctct cctacaggac tcaatccctg 540
 30 tctgcaacgg acccagtacc agcactgtgg cgtgaggtag gcacactcag agtcccccaa 600
 ggtgtagaat aagtctttaa acagtcaaaa acagatattt taaaaccag ggaattctgc 660
 tttggttgag aaacagcgcc ttctgagagc gaagaactca ttagttttta gccgtgatgg 720
 35 cgggtgaact gtcccaaggc agaatcgctc tctcctgtgt cattagtaca tcagctgaaa 780
 ggcaagcaaa cagttcttta cgtctgggaa agggctttaa ggcccgtgc ttgcgtgaag 840
 40 gggagatttg atgcagctat aaaccaggac atagacagga acaaaattcg gggtatttaa 900
 gcaaaattct ttagcagga aagggagggtg ggaaggagac cgaagggtga cgtcactggg 960
 gggagtggcc acagtcttaa gaaaagtcgg cggggctggg gagaccacaa ttgtgggaca 1020
 45 tagtctcagc 1030

<210> 8

<211> 954

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic Sequence

55

<400> 8

tccactctct agggcactct ccttggatat agtactgacc tctgtgctc actccctgga 60
 cgatcagtcc cagtgtctga aagggatatcc aggagttgag gagtagggaa caactgaggg 120
 ttggtaaaag tcggagcctg agggacctct aaggaaatgg caggggagat gagacatgtt 180
 65 ccgggagggt atgagattgc tcacatcttc ttctccactg gcctttgcgg tttggcccaa 240

tcgagtgagc ctttacgggt gttaagcctc cgttctccaa cccagagcaa aggctggcag 300
 tgctgccttc ttgaccgctg tcttgaggga tctgatctct gctcttgaca ccgcgcgctt 360
 5 taagggcacc agagcgggag agtcgtccgc gccaaaaggc tgcgagcctg actgctcttt 420
 tttggaggat gccaggttcc ctctcctaca ggactcaatc cctgtctgca acggacccag 480
 10 taccagcact gtggcggtgag gtacgcagac tcagagtccc ccaagggtgta gaataagtct 540
 ttaaacagtc aaaaacagat attttaaaac ccagggaatt ctgctttggt tgagaaacag 600
 cgccttctga gagcgaagaa ctcatagtt tttagcgggtg atggcgggtg aactgtccct 660
 15 aggagaatc gctctctcct gtgtcattag tacatcagct gaaaggcaag caaacagttc 720
 tttacgtctg ggaaagggct ttaaggcccg ctgcttgctg gaaggggaga tttgatgcag 780
 20 ctataaacca ggacatagac aggaacaaaa tacgggttat ttaagcaaaa ttcttttagca 840
 gggaaagggg ggtgggaagg agacggaagg gtgacgtcac tggggggagt ggccacagtc 900
 ttaagaaaag tcggcggggc tggggagacc acaattgtgg gacatagtct cagc 954
 25
 <210> 9
 <211> 878
 <212> DNA
 <213> Artificial Sequence
 30
 <220>
 <223> Description of Artificial Sequence: Synthetic
 Sequence
 35
 <400> 9
 ctgaaagggg atccaggagt tcaggagtag ggaacaactg aggggttgga aaagtcggag 60
 cctgaggggac ctctaaggaa atggcagggg agatgagtca tgttccggga ggctatgaga 120
 40 ttgctcagat cttcttctcc actggccttt gcggtttggc ccaatcgagt gaggctttac 180
 ggggtgtaag cctccgttct ccaaccaga gcaaaggctg gcagtgtgc cctcttgacc 240
 gctgtcttgg aggatctgat ctctgctctt gacaccgcgg gctttaaggg caccagagcg 300
 45 ggagagtcgt ccgcgccaaa aggtcccgag cctgactgct cttttttgga ggatgccagg 360
 ttccctctcc tacaggactc aatccctgtc tgcaacggac cgagtaccag cactgtggcg 420
 50 tgaggtacgc aactcagag tcccccaagg tgtagaataa gtctttaaac agtcaaaaac 480
 agatatatta aaaccaggg aattctgctt tggttgagaa acagcgcctt ctgagagcga 540
 agaactcatt agtathtagc ggtgatggcg ggtgaactgt cccaaggcag aatcgctctc 600
 55 tcctgtgtca ttagtacatc agctgaaagg caagcaaca gttctttacg tctgggaaag 660
 ggctttaagg ccgctgctt gcgtgaaggg gagatttgat gcagcaataa accaggacat 720
 60 agacaggaac aaaattcggg ttatttaagc aaaattcttt agcagggaaa gggaggtggg 780
 aaggagacgg aagggtgacg tcaactggggg gagtggccac agtcttaaga aaagtcggcg 840
 65 gggctgggga gaccacattt gtgggacata gtctcagc 878

<210> 10
 <211> 876
 <212> DNA
 <213> Artificial Sequence

5

<220>
 <223> Description of Artificial Sequence: Synthetic
 Sequence

10 <400> 10
 ctgaaagggg atccaggagt tcaggagtag ggaacaactg agggttggta aaagtcggag 60
 cctgagggac ctctaaggaa atggcagggg agatgagtca tgttccggga ggctatgaga 120
 15 ttgctcagat cttcgtctcc actggccttt gcggtttggc ccaatcgagt gaggcctttac 180
 ggggtgtaag cctccgttct ccaaccaga gcaaaggctg gcagtgtctc cctcttgacg 240
 20 ctgtcttgga ggatctgatc tctgtctttg acaccgcggg ctttaagggc accagagcgg 300
 gagagtcgtc cgcgccaaaa ggctgcgagc ctgactgtc ttttttggag gatgccaggt 360
 tccctctcct acaggactca atccctgtct gcaacggacc cagtaccagc actgtggcgt 420
 25 gaggtacgca cactcagatg tcccccaagg tgtagaataa gtctttaaac atcaaaaaca 480
 gatattttta aaccagggga attctgcttt ggttgagaaa cagcgccttc tgagagcgaa 540
 gaactcatta gtttttagcg gtgatggcgg gtgaactgtc ccaaggcaga attcgtcttc 600
 30 tctgtgtca ttagtacatc agctgaaagg caagcaaaca gttctttacg tctgggaaag 660
 ggctttaagg cccgctgctt gcgtgaaggg gagattgatg cagctataaa ccaggacata 720
 35 gacaggaaca aaattcgggt tattaagcaa aattcttttag cagggaaagg gaggtgggaa 780
 ggagacggaa ggggtgacgtc actgggggga gtggccacag tcttaagaaa agtcggcggg 840
 40 gctggggaga ccacaattgt gggacatagt ctcagc 876

<210> 11
 <211> 1096
 <212> DNA
 <213> Artificial Sequence

45

<220>
 <223> Description of Artificial Sequence: Synthetic
 Sequence

50

<400> 11
 acacaacctt gttaagacta tgtagcttc cagcagagaa aagcagctgt aaagacacaa 60
 attcaagaag gaaaccctgg gagaatggcc cctggctttc ctctgggatc ttctgtgccg 120
 55 tgtatccgct acccggggcg atttctgtgc tccactgtct agggcactct ccttggatat 180
 agtactgacc tctgtgtc agtccttga cgatcagtc cagtgtctga aagggtatcc 240
 60 aggagttgag gagtagggac aactgagggt tggtaaaagt cggagcctga gggacctcta 300
 aggaaatcgc aggggagatg agacatgttc cgggaggcta tgagattgct cagatcttct 360
 tctccactgg cctttgcggt ttggccaat cgagtgaacc tttacgggtg ttaagcctcc 420
 65 gttctccaac ccagagcaaa ggctggcagt gctgccctct tgacgtgtc ttgcaggatc 480

5 tgatctctgc tcttgacacc gcgggcttaa gggcaccaga gcgggagagt cgtccgcgcc 540
 aaaaggctgc gagcctgact gctctttttt ggaggatgcc aggttccttc tcctacagga 600
 ctcaatccca gtctgcaacg gacccagtag cagcactgtg gcgtgaggta cgcacactca 660
 10 gagtccccca aggtgtagaa taagtcttta aacagtcaaa aacagatatt taaaaccag 720
 ggaattctgc tttggttgag aaacagcgcc ttctgagagc gaagaactca ttagttttta 780
 gcggtgatgg cgggtgaact gtcccaaggc agaatcgctc tctcctgtgt cattagtaca 840
 15 tcagtgaag gcaagcaaac agttctttac gtctgggaaa gggctttaag gcccgctgct 900
 tgcgtgaagg gcagatttga tgcagctata aaccaggaca tagacagaac aaaattcggg 960
 ttatttaagc aaaattcttt agcaggaaag ggaggtggga aggagacgga aggggtgacgt 1020
 20 cactgggggg agtggccaca gtcttaagaa aagtcggcgg gcctggggag accacaattg 1080
 gggacatagt ctcagc 1096

25 <210> 12
 <211> 43
 <212> DNA
 <213> Artificial Sequence

30 <220>
 <223> Description of Artificial Sequence: Synthetic
 Sequence

35 <400> 12
 cagcctcgga atgagctgcc acaactgctc cgacccccag gtc 43

40 <210> 13
 <211> 59
 <212> DNA
 <213> Artificial Sequence

45 <220>
 <223> Description of Artificial Sequence: Synthetic
 Sequence

50 <400> 13
 ttctgccagc tactcttcga catggagttc ttcgtgtggc acctgctgca ccacaaggt 59

55 <210> 14
 <211> 76
 <212> DNA
 <213> Artificial Sequence

60 <220>
 <223> Description of Artificial Sequence: Synthetic
 Sequence

65 <400> 14
 cagactggag cccttcgggt ggtacggggg tgtggtgcac cacgacctgc atcactctca 60
 ctttaactgc aacttc 76

65 <210> 15

<211> 53
<212> DNA
<213> Artificial Sequence

5 <220>
<223> Description of Artificial Sequence: Synthetic
Sequence

10 <400> 15
tccactcgta gggcactctc cttggatata gtactgacct cctgtgctca gtc 53

15 <210> 16
<211> 54
<212> DNA
<213> Artificial Sequence

20 <220>
<223> Description of Artificial Sequence: Synthetic
Sequence

<400> 16
tccactctgt agggcactct ccttggatat agtactgacc tcctgtgctc agtc 54

25

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 99/24873

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/53 C12N9/02 C12N5/10 C12N1/19

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	LUND, ERIK G. ET AL: "cDNA cloning of mouse and human cholesterol 25-hydroxylases, polytopic membrane proteins that synthesize a potent oxysterol regulator of lipid metabolism" J. BIOL. CHEM., vol. 273, no. 51, 18 December 1998 (1998-12-18), pages 34316-34327, XP002131143 the whole document — -/-	1-30

☒ Further documents are listed in the continuation of box C.☐ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the International filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the International filing date but later than the priority date claimed

"T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the International search

22 February 2000

Date of mailing of the International search report

08/03/2000

Name and mailing address of the ISA

European Patent Office, P.B. 6818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Lejeune, R

INTERNATIONAL SEARCH REPORT

Inter. Appl. No.

PCT/US 99/24873

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMBL 'Online! AC A0225427, 28 September 1998 (1998-09-28) MAHAIRAS G G ET AL: "HS_2003_B1_E03_T7 CIT Approved Human Genomic Sperm Library D Homo sapiens genomic clone Plate=2003 Col=9 Row=J, genomic survey sequence" XP002131144 99% identity in 300 BP overlap with SEQ ID NO 1</p>	8-12
X	<p>DATABASE EMBL 'Online! AC W01328, 25 April 1996 (1996-04-25) HILLIER L ET AL: "yy66b12.r1 Soares multiple sclerosis 2NbHMSF Homo sapiens cDNA clone 278495 5' similar to contains element MER22 repetitive element ;."</p> <p>XP002131145 cited in the application 96.3% identity in 380 BP overlap with SEQ ID NO 1</p>	8-12
X	<p>DATABASE EMBL 'Online! AC AI081548, 17 August 1998 (1998-08-17) NCI-CGAP: "on04h07.x1 NCI_CGAP_Kid3 Homo sapiens cDNA clone IMAGE:1555741 3', mRNA sequence" XP002131146 cited in the application 100% identity in 589 BP overlap with SEQ ID NO 1</p>	8-12
X	<p>DATABASE EMBL 'Online! AC AI169398, 8 October 1998 (1998-10-08) LEE N H ET AL: "EST215244 Normalized rat kidney, Bento Soares Rattus sp. cDNA clone RKIBR78 3' end, mRNA sequence." XP002131147 86.2% identity in 407 BP overlap with SEQ ID NO 3</p>	8-12
X	<p>DATABASE EMBL 'Online! AC AA289153, 16 April 1997 (1997-04-16) MARRA M ET AL: "vb35g09.r1 Soares mouse lymph node NbMLN Mus musculus cDNA clone 750976 5'." XP002131148 cited in the application 99.3 % identity in 438 BP overlap with SEQ ID NO 3</p>	8-12
	-/-	

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 99/24873

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p> DATABASE EMBL 'Online! AC AA285796, 10 April 1997 (1997-04-10) MARRA M ET AL: "vb89e08.r1 Soares mouse 3NbMS Mus musculus cDNA clone 764198 5'" XP002131149 cited in the application 99.1% identity in 444 BP overlap with SEq ID NO 3 </p>	8-12